<SEC-DOCUMENT>0001104659-24-128064.txt : 20241212
<SEC-HEADER>0001104659-24-128064.hdr.sgml : 20241212
<ACCEPTANCE-DATETIME>20241212165845
ACCESSION NUMBER:		0001104659-24-128064
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20241210
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241212
DATE AS OF CHANGE:		20241212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ROCKWELL MEDICAL, INC.
		CENTRAL INDEX KEY:			0001041024
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				383317208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23661
		FILM NUMBER:		241545673

	BUSINESS ADDRESS:	
		STREET 1:		30142 WIXOM ROAD
		CITY:			WIXOM
		STATE:			MI
		ZIP:			48393
		BUSINESS PHONE:		8004493353

	MAIL ADDRESS:	
		STREET 1:		30142 WIXOM ROAD
		CITY:			WIXOM
		STATE:			MI
		ZIP:			48393

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	20120530

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL, INC.
		DATE OF NAME CHANGE:	20120525

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ROCKWELL MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19970722
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2430838d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:rmti="http://rockwellmed.com/20241210">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_rmti_rockwellmed.com_20241210 -->
<!-- Field: Set; Name: xdx; ID: xdx_04B_20241210_20241210 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001041024 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2024-12-10" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2024-12-10" id="Fact000004" name="dei:EntityCentralIndexKey">0001041024</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="rmti-20241210.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2024-12-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001041024</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-12-10</xbrli:startDate>
        <xbrli:endDate>2024-12-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><b>UNITED STATES</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 18pt"><b>SECURITIES AND
EXCHANGE COMMISSION</b></span></p>

<p style="font: 18pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 18pt"><b>Washington,
D.C. 20549</b></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: capitalize; text-align: center"><span style="text-transform: capitalize"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: capitalize; text-align: center"><span style="text-transform: capitalize"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM&#160;<span id="xdx_909_edei--DocumentType_c20241210__20241210_zA24leuVwmt4"><ix:nonNumeric contextRef="AsOf2024-12-10" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section&#160;13 or
15(d) of</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<b><span id="xdx_906_edei--DocumentPeriodEndDate_c20241210__20241210_zVf8OPeilmSd"><ix:nonNumeric contextRef="AsOf2024-12-10" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">December 10, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90E_edei--EntityRegistrantName_c20241210__20241210_zFT0KAmdnJk" style="text-transform: uppercase"><b><ix:nonNumeric contextRef="AsOf2024-12-10" id="Fact000011" name="dei:EntityRegistrantName">Rockwell
Medical, Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its
charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20241210__20241210_zG5eX3K3c8wk"><ix:nonNumeric contextRef="AsOf2024-12-10" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--EntityFileNumber_c20241210__20241210_zGC424t4B1b8"><ix:nonNumeric contextRef="AsOf2024-12-10" id="Fact000013" name="dei:EntityFileNumber">000-23661</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; font-size: 10pt; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20241210__20241210_zm6xfU50vW0g"><ix:nonNumeric contextRef="AsOf2024-12-10" id="Fact000014" name="dei:EntityTaxIdentificationNumber">38-3317208</ix:nonNumeric></span></b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="vertical-align: top; text-align: center">(State or other jurisdiction <br/>
    of incorporation)</td>
    <td style="vertical-align: middle; font-size: 10pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
File Number)</span></td>
    <td style="vertical-align: top; text-align: center">(IRS Employer<br/>
    Identification No.)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_90C_edei--EntityAddressAddressLine1_c20241210__20241210_zEqWpuDu6Blh"><b><ix:nonNumeric contextRef="AsOf2024-12-10" id="Fact000015" name="dei:EntityAddressAddressLine1">30142
S. Wixom Road</ix:nonNumeric></b></span><b>, <span id="xdx_902_edei--EntityAddressCityOrTown_c20241210__20241210_zIM95ESPMeKb"><ix:nonNumeric contextRef="AsOf2024-12-10" id="Fact000016" name="dei:EntityAddressCityOrTown">Wixom</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressStateOrProvince_c20241210__20241210_zbvxPnJ33Kpc"><ix:nonNumeric contextRef="AsOf2024-12-10" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">Michigan</ix:nonNumeric></span></b> <b><span id="xdx_908_edei--EntityAddressPostalZipCode_c20241210__20241210_zWIcVVzmpfLe"><ix:nonNumeric contextRef="AsOf2024-12-10" id="Fact000018" name="dei:EntityAddressPostalZipCode">48393</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices, including
zip code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_906_edei--CityAreaCode_c20241210__20241210_zO9XakAcAiFe"><ix:nonNumeric contextRef="AsOf2024-12-10" id="Fact000019" name="dei:CityAreaCode">248</ix:nonNumeric></span>) <span id="xdx_90D_edei--LocalPhoneNumber_c20241210__20241210_zLCFHMMBpR77"><ix:nonNumeric contextRef="AsOf2024-12-10" id="Fact000020" name="dei:LocalPhoneNumber">960-9009</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>N/A</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 3pt auto; width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 90%; margin-left: 0.25in"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span id="xdx_90D_edei--WrittenCommunications_c20241210__20241210_zbvcAKfGkBwb" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-12-10" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span id="xdx_90A_edei--SolicitingMaterial_c20241210__20241210_zwgKX9y8Nulk" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-12-10" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span id="xdx_90C_edei--PreCommencementTenderOffer_c20241210__20241210_zERluu7PAzx5" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-12-10" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span id="xdx_901_edei--PreCommencementIssuerTenderOffer_c20241210__20241210_zORglUFskEvd" style="font-family: Wingdings"><ix:nonNumeric contextRef="AsOf2024-12-10" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c)</span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section&#160;12(b)&#160;of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 38%; text-align: center">Title&#160;of&#160;Each&#160;Class</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 20%; text-align: center">Trading&#160;
    Symbol</td><td style="font: bold 10pt Times New Roman, Times, Serif; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 38%; text-align: center">Name&#160;of&#160;Each&#160;exchange&#160;on&#160;which<br/>
 registered</td></tr>
<tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_908_edei--Security12bTitle_c20241210__20241210_zbmeX6dM5BHa"><ix:nonNumeric contextRef="AsOf2024-12-10" id="Fact000025" name="dei:Security12bTitle">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_90C_edei--TradingSymbol_c20241210__20241210_zMaF0hNMoeb5"><ix:nonNumeric contextRef="AsOf2024-12-10" id="Fact000026" name="dei:TradingSymbol">RMTI</ix:nonNumeric></span></td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span id="xdx_902_edei--SecurityExchangeName_c20241210__20241210_z47A4zuUGPrd"><ix:nonNumeric contextRef="AsOf2024-12-10" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2
of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Emerging
growth company <span style="font-family: Wingdings"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20241210__20241210_zJzGwSECKlHl"><ix:nonNumeric contextRef="AsOf2024-12-10" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.
</span><span style="font-family: Wingdings"><span style="font-family: Wingdings">&#168;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On December&#160;10, 2024, Rockwell Medical,&#160;Inc.
(the &#8220;Company&#8221;) announced the appointment of Jesse Neri as the Company&#8217;s Senior Vice President and Chief Financial Officer
effective immediately (the &#8220;Commencement Date&#8221;). Mr.&#160;Neri will also now serve as the Company&#8217;s Principal Financial
Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Mr.&#160;Neri, age 46, most recently served as
the Company&#8217;s Senior Vice President, Finance since October&#160;2023 and principal accounting officer since January&#160;2024. Prior
to joining the Company, Mr.&#160;Neri was the Executive Director of Finance at Hemavant Sciences and Aruvant Sciences, clinical-stage
biopharmaceutical companies that are members of the Roivant portfolio, from August&#160;2021 to October&#160;2023. From May&#160;2020
to August&#160;2021, Mr.&#160;Neri was a self-employed consultant. Mr.&#160;Neri served as Senior Vice President of Finance at Zyla Life
Sciences, a pharmaceutical company, from January&#160;2020 to May&#160;2020, as Vice President of Finance of Zyla from March&#160;2019
to January&#160;2020 and prior to that, as Executive Director, Financial Planning and Analysis and prior to that, as Senior Director of
Financial Planning and Analysis. Prior to Zyla, Mr.&#160;Neri served as Vice President of Financial Planning and Analysis at Symphony
Health Solutions. He started his career at Ellucian, a leading ERP software provider for higher education institutions, where he held
various roles of increasing responsibility. Mr.&#160;Neri received a B.S., Business Administration in Finance from Villanova University
and an M.B.A. from Drexel University LeBow School of Business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On October&#160;16, 2023, in connection with Mr.&#160;Neri&#8217;s
commencement of employment, the Company entered into an employment agreement with Mr.&#160;Neri (the &#8220;Employment Agreement&#8221;).
The Employment Agreement provides that Mr.&#160;Neri will serve as an at-will employee. Mr.&#160;Neri receives an annualized base salary
of $300,000 (subject to adjustment), is eligible to earn year-end performance bonuses with a target bonus opportunity of 45% of his base
salary, and is eligible to participate in the employee benefit plans and programs generally available to the Company&#8217;s similarly
situated senior executives. Mr.&#160;Neri is also eligible to receive annual long-term incentive grants consistent with similar practices
for the Company&#8217;s senior executives, awarded at the discretion of the Compensation Committee of the Board. In connection with his
commencement of employment, he received an initial equity grant comprised of a time-based option to purchase up to 75,000 shares of the
Company&#8217;s common stock that vests in equal installments on each of the first four anniversaries of October&#160;16, 2023 (the &#8220;Initial
Time-Based Options&#8221;). The Initial Time-Based Options were issued outside of the Company&#8217;s stockholder-approved Amended and
Restated 2018 Long-Term Incentive Plan, in accordance with Nasdaq Listing Rule&#160;5635(c)(4).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Employment Agreement, upon a termination
of Mr.&#160;Neri&#8217;s employment due to death or Disability, any equity awards held by Mr.&#160;Neri subject to time-based vesting
conditions (the &#8220;Time-Based Awards&#8221;) will accelerate and become fully vested. All stock options held by Mr.&#160;Neri that
are exercisable as of the date of such termination, including any stock options that accelerate in connection with such termination, will
remain exercisable until the earlier of one year following such termination and the expiration date of the stock options. Under the Employment
Agreement, upon a termination of Mr.&#160;Neri&#8217;s employment by the Company without Cause or by Mr.&#160;Neri for Good Reason, (i)&#160;Mr.&#160;Neri
will be entitled to receive, subject to his execution and non-revocation of a separation agreement and release of claims in favor of the
Company and compliance with certain restrictive covenants, (A)&#160;an amount equal to his base salary then in effect, payable in equal
installments for a one-year period, and (B)&#160;reimbursement of COBRA coverage for up to one year (or, if sooner, until he receives
substantially similar coverage from another employer), and (ii)&#160;(A)&#160;the Time-Based Awards will continue to vest for a period
of one year and (B)&#160;all stock options held by Mr.&#160;Neri that are exercisable as of the date of such termination and all stock
options that become exercisable over the one-year period following such termination will remain exercisable until the earlier of one year
following such termination and the expiration date of the stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Under the Employment Agreement, in the event of
a Change of Control, upon a termination of Mr.&#160;Neri&#8217;s employment by the Company without Cause or by Mr.&#160;Neri for Good
Reason during the Effective Period, subject to his compliance with certain restrictive covenants, (i)&#160;Mr.&#160;Neri will be entitled
to receive (A)&#160;an amount equal to the sum of (1)&#160;1.5 times his base salary then in effect plus (2)&#160;100% of his annual target
bonus, and (B)&#160;reimbursement of COBRA coverage for up to one year (or, if sooner, until he receives substantially similar coverage
from another employer or is no longer eligible for COBRA coverage) and (ii)&#160;(A)&#160;any Time-Based Awards will accelerate and become
fully vested and (B)&#160;all stock options held by Mr.&#160;Neri that are exercisable as of the date of such termination, including any
stock options that accelerate in connection with such termination, will remain exercisable until the expiration date of the stock options.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the Employment Agreement, Mr.&#160;Neri
also entered into the Company&#8217;s form of Employee Confidentiality, Assignment of Inventions, Non-Interference and Non-Competition
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Capitalized terms used herein, but not defined,
shall have the meanings given to them in the Employment Agreement. The foregoing summary of the Employment Agreement does not purport
to be a complete description of the Employment Agreement and is qualified in its entirety by reference to the full text of the Employment
Agreement, a copy of which is attached hereto as Exhibit&#160;10.1 and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">Item&#160;9.01
</span></b></span><b><span style="text-decoration: underline">Financial Statements and Exhibits.</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">EXHIBIT&#160;INDEX</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1pt solid; width: 89%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2430838d1_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2430838d1_ex10-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated as of October&#160;16, 2023, between the Company and Jesse Neri.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page&#160;Interactive Data File, formatted in INline XBRL and included as Exhibit&#160;101.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span style="text-decoration: underline">SIGNATURE</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ROCKWELL MEDICAL,&#160;INC.</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December&#160;12, 2024</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&#160;Mark Strobeck</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mark Strobeck, Ph.D.</span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>



<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjUEKwkAMRU/QO4RZS20H3XRpURGrSBFxO9oog+2kZMaqR/KWxhYxfAjh//ej1EgtaWFrZDjOygL22LS1CQglXpDRnVES+WqdgewSr9YHNi705w/MSRgUZhrryUmMPtpZj1UGaToW6Qkk00xr2G1U9PVzchdboQvW1GBcBTumli0Gw6+hYW+e5Kh59a8OyN6Sk7o4Gew36CTVsKXOPIhvHooiV9Gon0gtme6tpObPgO5LwrzGRt75gf4r+gAECEqI -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2430838d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">Exhibit&nbsp;10.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Employment
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Employment Agreement
(the &ldquo;<I>Agreement</I>&rdquo;) is made as of October&nbsp;16, 2023 (the &ldquo;<I>Effective Date</I>&rdquo;), by and between Rockwell
Medical,&nbsp;Inc., a Delaware corporation (the &ldquo;<I>Company</I>&rdquo;), and Jesse Neri (&ldquo;<I>Executive</I>&rdquo;), subject
to the terms and conditions defined in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company and Executive
desire the Executive be employed by the Company to act as the Company&rsquo;s SVP, Finance, subject to the terms and conditions set forth
in this Agreement and such policies and procedures as the Company may from time to time implement and that are provided to the Executive;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in consideration
of the covenants contained herein, and for other valuable consideration, the Company and Executive hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify"><U>Certain Definitions</U>. Certain definitions used herein shall
have the meanings set forth on <U>Exhibit&nbsp;A</U> attached hereto.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify"><U>Executive&rsquo;s Duties and Obligations</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Duties;
Start Date</U>. Executive shall serve as the Company&rsquo;s SVP, Finance effective on October&nbsp;16, 2023, or such other mutually agreeable
date (such date being referred to herein as the &ldquo;<I>Commencement Date</I>&rdquo;). Executive shall report to the President and Chief
Executive Officer of the Company (&ldquo;<I>CEO</I>&rdquo;). Executive shall have those duties and responsibilities customarily associated
with the position of SVP, Finance of a publicly-traded company of the size and nature of the Company, and such other additional duties
and responsibilities consistent with Executive&rsquo;s position as may, from time to time, be assigned to Executive by the CEO or the
board of directors of the Company (the &ldquo;<I>Board</I>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>At-Will
Employment</U>. Executive&rsquo;s employment shall be on an at-will basis, meaning that either party may terminate this employment arrangement
at any time and without cause. The term of this Agreement shall be from the Effective Date through the applicable date of termination
(the &ldquo;<I>Term</I>&rdquo;). On the date of termination of employment, Executive acknowledges that he shall immediately be deemed
to have resigned all employment and related job duties and responsibilities with the Company, including, without limitation, any positions
on any Company committees or other similar positions of an affiliated company. Executive agrees to sign all reasonable documentation evidencing
the foregoing as may be presented to Executive for signature by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Confidential
Information and Inventions Matters</U>. In consideration of the covenants contained herein, Executive has executed and agrees to be
bound by the Company&rsquo;s form of Employee Confidentiality, Assignment of Inventions, Non-Interference and Non-Competition
Agreement (the &ldquo;<I>Confidentiality Agreement</I>&rdquo;), in the form attached to this Agreement as <U>Exhibit&nbsp;B</U>.
Executive shall comply in all material respects at all times with the terms and conditions of the Confidentiality Agreement and all
other reasonable policies of the Company governing its confidential and proprietary information. In the event that Executive
breaches any provisions of this Agreement or the Confidentiality Agreement, then, in addition to any other rights which the Company
may have, the Company shall be entitled, without the posting of a bond or other security, to seek injunctive relief to enforce the
restrictions contained therein. In the event that an actual proceeding is brought in equity to enforce the provisions of this
Agreement or the Confidentiality Agreement, Executive shall not assert as a defense that there is an adequate remedy at law, nor
shall the Company be prevented from seeking any other remedies which may be available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Location
of Office</U>. Executive&rsquo;s primary office location will be his home office, which is currently in Newtown Square, Pennsylvania,
or such other office as may be established by the Company from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify"><U>Devotion of Time to Company&rsquo;s Business</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Full-Time
Efforts</U>. During Executive&rsquo;s employment with the Company, Executive shall devote substantially all of Executive&rsquo;s business
time, attention and efforts to the proper performance of Executive&rsquo;s duties and obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Other Employment</U>. During Executive&rsquo;s employment with the Company, Executive shall not, except as otherwise provided herein,
directly or indirectly, render any services of a commercial or professional nature to any other person or organization, whether for compensation
or otherwise, without the prior written consent of the CEO; <I>provided, however</I>, that it shall not be a violation or breach of this
Agreement for Executive to (i)&nbsp;accept speaking or presentation engagements in exchange for honoraria; (ii)&nbsp;serve on boards of
charitable organizations or participate in charitable, educational, religious or civic activities; (iii)&nbsp;attend to his and his family&rsquo;s
personal affairs; or (iv)&nbsp;own no more than three percent (3%) of the outstanding equity securities of a corporation whose stock is
listed on a national stock exchange, so long as such activities are not adverse to the Company&rsquo;s interests and do not materially
interfere with the performance of Executive&rsquo;s duties hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify"><U>Compensation and Benefits</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Base
Compensation</U>. During the Term, the Company shall pay to Executive base annual compensation (&ldquo;<I>Base Salary</I>&rdquo;) of $300,000
(with a gross amount of $11,538.46 paid to Executive on a bi-weekly basis), payable in accordance with the Company&rsquo;s regular payroll
practices and less all required withholdings benefits as hereinafter set forth in this Section&nbsp;4. Executive&rsquo;s Base Salary shall
be reviewed annually and may be increased based on an assessment of Executive&rsquo;s performance, the performance of the Company, inflation,
the then prevailing salary scales for comparable positions and other relevant factors; provided, however, that any increase in Base Salary
shall be solely within the discretion of the Compensation Committee of the Company&rsquo;s Board. Executive&rsquo;s Base Salary may not
be subject to reduction from the level set forth above or such later increased level as determined by the Compensation Committee, unless
pursuant to a salary reduction program of general application to senior executives of the Company, provided that, unless agreed to in
writing by Executive, the percentage reduction of Executive&rsquo;s Base Salary shall not be greater than the percentage reduction applied
to any other senior executive of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Annual
Bonus</U>. During the Term and commencing in 2023, Executive shall be eligible for year-end bonuses, which shall be paid in cash
(any such bonus an &ldquo;<I>Annual Bonus</I>&rdquo;), In a target amount equal to 35% of Executive&rsquo;s Base Salary, as then in
effect (the &ldquo;<I>Target Bonus</I>&rdquo;), as may be awarded pursuant to any annual executive bonus plan and related
performance goals established by the CEO and the achievement of corporate goals approved solely at the discretion of the
Compensation Committee of the Board. Any such Annual Bonus shall contain such rights and features as are typically afforded to other
senior executives of the Company. To be eligible to receive an Annual Bonus, the Executive must be employed by the Company on the
date such bonuses are paid. Executive&rsquo;s Annual Bonus shall be pro-rated to eighty percent (80%) of his Target Bonus for
2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Long-Term
Incentive Grants</U>. As of the Commencement Date, the Executive will eligible to participate in the Company&rsquo;s Amended and Restated
2018 Long Term Incentive Plan (the &ldquo;<I>Plan</I>&rdquo;). Such awards will be subject in all respects to the terms and conditions
of the Plan and the forms of award agreement adopted by the Board for use thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Initial
Option Grant</U>. Subject to Board or Compensation Committee approval, and as a material inducement to Executive agreeing to join the
Company, Executive shall be awarded an option to purchase up to 75,000 shares of common stock outside of the Company&rsquo;s stockholder-approved
equity incentive plans, as permitted under applicable Nasdaq rules&nbsp;(the &ldquo;<I>Option</I>&rdquo;). The Option will have an exercise
price equal to the closing price of the Company&rsquo;s common stock on the Commencement Date and will vest and become exercisable as
follows: 18,750 will vest and become exercisable on each of the first four anniversaries of the date of grant, subject to the Executive&rsquo;s
continued service through each applicable vesting date. The terms and conditions of the Option will also be subject to the applicable
award agreement, provided that the Option shall be issued outside of the Company&rsquo;s shareholder-approved equity incentive plans,
as permitted under applicable Nasdaq rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Annual
Equity Grants</U>. During the Term, Executive shall be eligible to receive annual long-term incentive grants consistent with similar practices
for the Company&rsquo;s senior executives, which may be paid in either cash or equity, or both (any such grants a &ldquo;<I>Long- Term
Incentive Grant</I>&rdquo;), as may be awarded solely at the discretion of the Compensation Committee of the Board; provided that the
Compensation Committee shall be under no obligation whatsoever to grant such discretionary Long-Term Incentive Grants. Any Long-Term Incentive
Grants issued to Executive shall be governed by the Company&rsquo;s then-applicable long-term incentive plan(s)&nbsp;and any long-term
incentive grant agreement(s)&nbsp;under the then applicable long-term incentive plan(s)&nbsp;under which they are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Benefits</U>.
During the Term, Executive shall be entitled to participate in all employee benefit plans, programs and arrangements (health, dental,
disability, 401k,&nbsp;etc.) made available generally to the Company&rsquo;s senior executives or to its employees on substantially the
same basis that such benefits are provided to such senior executives; provided, however, that nothing in this Agreement shall be construed
to require the Company to establish or maintain any particular plans, programs or arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Vacations</U>.
During the Term, Executive shall be entitled to 20 days paid time off (&ldquo;<I>PTO</I>&rdquo;) days, to be earned ratably
throughout the year starting on the Commencement Date. PTO days may be only carried from one year to the next in accordance with the
Company PTO policy, provided that the Executive shall not be entitled to carry forward into the following year a balance of more
than 10 PTO days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Reimbursement
of Business Expenses</U>. Executive is authorized to incur reasonable expenses in carrying out Executive&rsquo;s duties and responsibilities
under this Agreement and the Company shall reimburse Executive for all reasonable expenses, in accordance with and subject to the applicable
policies and procedures of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify"><U>Termination of Employment</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination
by the Company for Cause or Termination by Executive without Good Reason, Death or Disability</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the event of a termination of Executive&rsquo;s employment by the Company for Cause, a termination by Executive without Good Reason, or
in the event this Agreement terminates by reason of the death or Disability of Executive, Executive shall be entitled to any unpaid compensation
accrued through the last day of Executive&rsquo;s employment and payment of any other amounts owing to Executive but not yet paid, less
any amounts owed by Executive to the Company (the &ldquo;<I>Accrued Amounts</I>&rdquo;). Executive shall not be entitled to receive any
other compensation or benefits from the Company whatsoever (except as provided below and as and to the extent the continuation of certain
benefits is required by law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
the case of a termination due to death or Disability, notwithstanding any provision to the contrary in any stock option, restricted stock
or other equity award agreement between the Company and Executive, (x)&nbsp;all shares underlying Executive&rsquo;s time-based outstanding
equity awards, including all options that are time-based awards (as opposed to performance-based) to acquire Company stock held by Executive
(the &ldquo;<I>Time-Based Awards</I>&rdquo;) shall accelerate and become fully vested upon the Date of Termination and shall thereupon
remain fully exercisable until the earlier of (i)&nbsp;one (1)&nbsp;year from date of termination due to death or Disability or (ii)&nbsp;the
expiration of their stated terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination
by the Company without Cause or by Executive for Good Reason</U>. If (x)&nbsp;Executive&rsquo;s employment is terminated by the
Company other than for Cause, death or Disability (i.e., without Cause) or (y)&nbsp;Executive terminates employment with Good
Reason, then Executive will receive the Accrued Amounts and, on the condition that the Executive signs a separation agreement
containing a release of claims in the form attached as <U>Exhibit&nbsp;C</U> hereto (subject to any changes required by applicable
law), which such release becomes final, binding and irrevocable within 30 days after the Date of Termination (or such longer period
of time as required by applicable law), the Executive shall also be entitled to receive the following from the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;An
amount equal to the twelve (12) months of Executive&rsquo;s Base Salary then in effect; payable in equal installments in accordance with
the Company&rsquo;s regular payroll schedule, from the Date of Termination to the date that is twelve (12) months after the Date of Termination
(the &ldquo;<I>Severance Period</I>&rdquo;); provided, however, that each installment payable before the release becomes final, binding
and irrevocable shall not be paid to the Executive until such release becomes final, binding and irrevocable (at which time all such amounts
that would have been paid but for the delay described in this clause (i)&nbsp;shall be paid); provided further, however, that if the time
period for the release to be executed and become irrevocable spans two calendar years, the installment payments due once the release becomes
final, binding and irrevocable shall be paid no earlier than January&nbsp;1 of the later calendar year;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;During
the Severance Period, if Executive elects to continue Company medical benefits through the Consolidated Omnibus Budget Reconciliation
Act of 1985 (&ldquo;<I>COBRA</I>&rdquo;), the Company shall reimburse the Executive for the out-of-pocket cost of continuing medical benefits,
on the same terms and conditions as such benefits are provided to active employees of the Company, for up to twelve (12) months. The Company&rsquo;s
obligation under this Section&nbsp;5(b)(ii)&nbsp;shall terminate or be reduced to the extent that substantially similar coverage is provided
by a subsequent employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Subject
to the release becoming final, binding and irrevocable, notwithstanding any provision to the contrary in any stock option or restricted
stock or other equity award agreement between the Company and the Executive, the Time-Based Awards shall continue to vest over the Severance
Period and all vested stock options to acquire Company stock and all other similar vested equity awards held by the Executive as of the
Date of Termination shall continue to be exercisable for a period of one year from the Date of Termination, or, if earlier, until the
ultimate expiration date of such awards; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
the foregoing, if Executive engages in a material breach of any provision of this Agreement or the Confidentiality Agreement during the
Severance Period (or the period applicable to such obligation, if shorter or longer), and such breach is not cured within ten business
days after receipt from the Company of notice thereof, then the Company&rsquo;s continuing obligations under this Section&nbsp;5(b)&nbsp;shall
cease as of the date of the breach and the Executive shall be entitled to no further payments or benefits hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Termination
in connection with a Change of Control</U>. In the event of a Change of Control, if Executive&rsquo;s employment is terminated by the
Company other than for Cause or by Executive for Good Reason during the Effective Period, then Executive shall be entitled to receive
the following from the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">The Accrued Amounts;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Within
10 days after the Date of Termination, a lump sum cash payment equal to the Target Bonus, multiplied by the fraction obtained by dividing
the number of days Executive was employed during the calendar year in which the Date of Termination occurs by 365;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Within
10 days after the Date of Termination, a lump sum cash payment in an amount equal to 1 times the Executive&rsquo;s annual Base
Salary then in effect (as determined without regard to any reduction in such Base Salary constituting Good Reason); <I>provided,
however</I>, that if Executive&rsquo;s employment is terminated prior to the consummation of a Change of Control but under
circumstances that would cause the Change of Control Date to precede the date that the Change of Control is consummated, such amount
will be paid in equal installments in accordance with the Company&rsquo;s regular payroll schedule over the Benefit Period (defined
below), subject to all remaining installments being paid in a lump sum on the date on which the Change of Control is
consummated;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
Executive elects to continue Company medical benefits under COBRA, for a period of twelve months following the Date of Termination (the
 &ldquo;<I>Benefit Period</I>&rdquo;), the Company shall reimburse the Executive for the out-of-pocket cost of continuing medical benefits
for such period on the same terms and conditions as such benefits are provided to active employees of the Company. The Company&rsquo;s
obligation under this Section&nbsp;5(c)(iv)&nbsp;shall terminate or be reduced to the extent that substantially similar coverage is provided
by a subsequent employer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
any provision to the contrary in any stock option, restricted stock or other equity award agreement between the Company and Executive,
all shares underlying Executive&rsquo;s Time-Based Awards shall accelerate and become fully vested upon the Date of Termination and all
restrictions thereon shall be lifted in accordance with the terms of the stock option or other award agreements evidencing such Time-Based
Awards, and all such exercisable time-based stock options shall continue to be exercisable for the remainder of their stated terms; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
the foregoing, if Executive engages in a material breach of any provision of this Agreement or Executive&rsquo;s Confidentiality Agreement
during the Benefits Period, and such breach is not cured within ten business days after receipt from the Company of notice thereof, then
the Company&rsquo;s continuing obligations under this Section&nbsp;5(c)&nbsp;shall cease as of the date of the breach and the Executive
shall be entitled to no further payments or benefits hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify"><U>Notice of Termination</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Any
termination of Executive&rsquo;s employment by the Company for Cause, or by Executive for Good Reason shall be communicated by a
Notice of Termination to the other party hereto given in accordance with Section&nbsp;10. For purposes of this Agreement,
 &ldquo;<I>Notice of Termination</I>&rdquo; means a written notice which: (i)&nbsp;is given at least 10 days prior to the Date of
Termination (at least 30 days in the case of Notice of Termination given by Executive for Good Reason, following the notice and cure
period set forth below in the definition of Good Reason); (ii)&nbsp;indicates the specific termination provision in this Agreement
relied upon; (iii)&nbsp;to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a
basis for termination of Executive&rsquo;s employment under the provision so indicated; and (iv)&nbsp;specifies the employment
termination date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;A
termination of employment of Executive will not be deemed to be for Good Reason unless Executive gives the Notice of Termination
provided for herein within 30 days after Executive has actual knowledge of the act or omission of the Company constituting such Good
Reason and Executive gives the Company a 30-day cure period to rectify or correct the condition or event that constitutes Good
Reason and Executive delivers final Notice of Termination within 30 days of the date that Company&rsquo;s failure to cure deadline
has expired, which final Notice of Termination must specify a Date of Termination of no later than 30 days after the final Notice of
Termination is provided.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Mitigation
of Damages</U>. Executive will not be required to mitigate damages or the amount of any payment or benefit provided for under this Agreement
by seeking other employment or otherwise. Except as otherwise provided in Sections 5(b)(ii)&nbsp;and 5(c)(iv), the amount of any payment
or benefit provided for under this Agreement will not be reduced by any compensation or benefits earned by Executive as the result of
self-employment or employment by another employer or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify"><U>Excess Parachute Excise Tax</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Anything
in this Agreement to the contrary notwithstanding, in the event it shall be determined that any payment, award, benefit or distribution
(including any acceleration) by the Company or any entity which effectuates a transaction described in Section&nbsp;280G(b)(2)(A)(i)&nbsp;of
the Code to or for the benefit of Executive (whether pursuant to the terms of this Agreement or otherwise, but determined without regard
to any additional payments required under this Section&nbsp;8) (a &ldquo;<I>Payment</I>&rdquo;) would be subject to the excise tax imposed
by Section&nbsp;4999 of the Code or any interest or penalties are incurred with respect to such excise tax by Executive (such excise tax,
together with any such interest and penalties, are hereinafter collectively referred to as the &ldquo;<I>Excise Tax</I>&rdquo;), the Company
will automatically reduce such Payments to the extent, but only to the extent, necessary so that no portion of the remaining Payments
will be subject to the Excise Tax, unless the amount of such Payments that the Executive would retain after payment of the Excise Tax
and all applicable Federal, state and local income taxes without such reduction would exceed the amount of such Payments that the Executive
would retain after payment of all applicable Federal, state and local taxes after applying such reduction. Unless otherwise elected by
the Executive to the extent permitted under Code Section&nbsp;409A, the Company shall reduce or eliminate the Payments by first reducing
or eliminating any cash severance benefits (with the payments to be made furthest in the future being reduced first), then by reducing
or eliminating any accelerated vesting of stock options or similar awards, then by reducing or eliminating any accelerated vesting of
restricted stock or similar awards, then by reducing or eliminating any other remaining Payments; provided, that no such reduction or
elimination shall apply to any non-qualified deferred compensation amounts (within the meaning of Section&nbsp;409A of the Code) to the
extent such reduction or elimination would accelerate or defer the timing of such payment in manner that does not comply with Section&nbsp;409A
of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;All
determinations required to be made under this Section&nbsp;8, including the assumptions to be utilized in arriving at such determination,
shall be made by the Company&rsquo;s independent auditors or such other certified public accounting firm reasonably acceptable to Executive
as may be designated by the Company (the &ldquo;<I>Accounting Firm</I>&rdquo;) which shall provide detailed supporting calculations both
to the Company and Executive within 15 business days of the receipt of notice from Executive that there has been a Payment, or such earlier
time as is requested by the Company. All fees and expenses of the Accounting Firm shall be borne solely by the Company. Any determination
by the Accounting Firm shall be binding upon the Company and Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Legal
Fees</U>. Each party shall be responsible for its own legal fees and expenses in connection with any claim or dispute relating to this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notices</U>.
All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given if delivered
by hand, upon confirmation of a facsimile or email transmission or upon receipt when mailed within the continental United States by first
class certified mail, return receipt requested, postage prepaid, addressed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">if to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Rockwell Medical,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">30142 S. Wixom Rd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Wixom, MI 48393</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Attn: President and Chief Executive Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.5in">if to Executive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The address on file with the records of the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Addresses may be changed by written notice sent
to the other party at the last recorded address of that party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Withholding</U>.
The Company shall be entitled to withhold from payments due hereunder any required federal, state or local withholding or other taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Entire
Agreement</U>. This Agreement, together with <U>Exhibit&nbsp;A</U> and the Confidentiality Agreement, contains the entire agreement between
the parties with respect to the subject matter hereof and supersedes all other prior agreements, written or oral, with respect thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: justify"><U>Arbitration</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
the parties are unable to resolve any dispute or claim relating directly or indirectly to this Agreement or any dispute or claim between
Executive and the Company or its officers, directors, agents, or employees (a &ldquo;<I>Dispute</I>&rdquo;), then either party may require
the matter to be settled by final and binding arbitration by sending written notice of such election to the other party clearly marked
 &lsquo;Arbitration Demand.&rsquo; Such Dispute shall be arbitrated in accordance with the terms and conditions of this Section&nbsp;13.
Notwithstanding the foregoing, either party may apply to a court of competent jurisdiction for a temporary restraining order, a preliminary
injunction, or other equitable relief to preserve the status quo or prevent irreparable harm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Dispute shall be resolved by a single arbitrator in an arbitration administered by the American Arbitration Association in accordance
with its Employment Arbitration Rules&nbsp;and judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction
thereof. The decision of the arbitrator shall be final and binding on the parties, and specific performance giving effect to the decision
of the arbitrator may be ordered by any court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Nothing
contained herein shall operate to prevent either party from asserting counterclaim(s)&nbsp;in any arbitration commenced in accordance
with this Agreement, and any such party need not comply with the procedural provisions of this Section&nbsp;13 in order to assert such
counterclaim(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
arbitration shall be filed with the office of the American Arbitration Association (&ldquo;<I>AAA</I>&rdquo;) located in New York, New
York or such other AAA office as the parties may agree upon (without any obligation to so agree). The arbitration shall be conducted pursuant
to the Employment Arbitration Rules&nbsp;of AAA as in effect at the time of the arbitration hearing, such arbitration to be completed
in a 60-day period. In addition, the following rules&nbsp;and procedures shall apply to the arbitration:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
arbitrator shall have the sole authority to decide whether or not any Dispute between the parties is arbitrable and whether the party
presenting the issues to be arbitrated has satisfied the conditions precedent to such party&rsquo;s right to commence arbitration as required
by this Section&nbsp;13.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
decision of the arbitrator, which shall be in writing and state the findings, the facts and conclusions of law upon which the decision
is based, shall be final and binding upon the parties, who shall forthwith comply after receipt thereof. Judgment upon the award rendered
by the arbitrator may be entered by any competent court. Each party submits itself to the jurisdiction of any such court, but only for
the entry and enforcement to judgment with respect to the decision of the arbitrator hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
arbitrator shall have the power to grant all legal and equitable remedies (including, without limitation, specific performance) and award
compensatory and punitive damages if authorized by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
parties shall bear their own costs in preparing for and participating in the resolution of any Dispute pursuant to this Section&nbsp;13,
and the costs of the arbitrator(s)&nbsp;shall be equally divided between the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as provided in the last sentence of Section&nbsp;13(a), the provisions of this Section&nbsp;13 shall be a complete defense to any suit,
action or proceeding instituted in any federal, state or local court or before any administrative tribunal with respect to any Dispute
arising in connection with this Agreement. Any party commencing a lawsuit in violation of this Section&nbsp;13 shall pay the costs of
the other party, including, without limitation, reasonable attorney&rsquo;s fees and defense costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.</TD><TD STYLE="text-align: justify"><U>Miscellaneous</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Governing
Law</U>. This Agreement shall be interpreted, construed, governed and enforced according to the laws of the State of Delaware without
regard to the application of choice- of-law rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Amendments</U>.
No amendment or modification of the terms or conditions of this Agreement shall be valid unless in writing and signed by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Severability</U>.
If one or more provisions of this Agreement are held to be invalid or unenforceable under applicable law, such provisions shall be construed,
if possible, so as to be enforceable under applicable law, or such provisions shall be excluded from this Agreement and the balance of
the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Binding
Effect</U>. This Agreement shall be binding upon and inure to the benefit of the beneficiaries, heirs and representatives of Executive
(including the Beneficiary) and the successors and assigns of the Company. The Company shall require any successor (whether direct or
indirect, by purchase, merger, reorganization, consolidation, acquisition of property or stock, liquidation, or otherwise) to all or substantially
all of its assets, by agreement in form and substance satisfactory to Executive, expressly to assume and agree to perform this Agreement
in the same manner and to the same extent that the Company would be required to perform this Agreement if no such succession had taken
place. Regardless of whether such agreement is executed, this Agreement shall be binding upon any successor of the Company in accordance
with the operation of law and such successor shall be deemed the Company for purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Successors
and Assigns</U>. Except as provided in Section&nbsp;14(d)&nbsp;in the case of the Company, or to the Beneficiary in the case of the death
of Executive, this Agreement is not assignable by any party and no payment to be made hereunder shall be subject to anticipation, alienation,
sale, transfer, assignment, pledge, encumbrance or other charge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Remedies
Cumulative; No Waiver</U>. No remedy conferred upon either party by this Agreement is intended to be exclusive of any other remedy, and
each and every such remedy shall be cumulative and shall be in addition to any other remedy given hereunder or now or hereafter existing
at law or in equity. No delay or omission by either party in exercising any right, remedy or power hereunder or existing at law or in
equity shall be construed as a waiver thereof, and any such right, remedy or power may be exercised by such party from time to time and
as often as may be deemed expedient or necessary by such party in such party&rsquo;s sole discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Survivorship</U>.
Notwithstanding anything in this Agreement to the contrary, all terms and provisions of this Agreement that by their nature extend beyond
the termination of the Term shall survive such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Counterparts</U>.
This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of which, when taken together,
shall constitute one document. Signatures to this Agreement may be delivered by any electronic means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Section&nbsp;409A
of the Code</U>. The intent of the parties is that payments and benefits under this Agreement comply with, or be exempt from, Section&nbsp;409A
of the Code and, accordingly, to the maximum extent permitted, this Agreement shall be construed and interpreted in accordance with such
intent. Executive&rsquo;s termination of employment (or words to similar effect) shall not be deemed to have occurred for purposes of
this Agreement unless such termination of employment constitutes a &ldquo;separation from service&rdquo; within the meaning of Code Section&nbsp;409A
and the regulations and other guidance promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Notwithstanding
any provision to the contrary in this Agreement, if Executive is deemed on the date of Executive&rsquo;s termination to be a &ldquo;specified
employee&rdquo; within the meaning of that term under Code Section&nbsp;409A(a)(2)(B)&nbsp;and using the identification methodology selected
by the Company from time to time, or if none, the default methodology set forth in Code Section&nbsp;409A, then with regard to any payment
or the providing of any benefit that constitutes &ldquo;non-qualified deferred compensation&rdquo; pursuant to Code Section&nbsp;409A
and the regulations issued thereunder and not exempt from Code Section&nbsp;409A as a short-term deferral or otherwise that is payable
due to Executive&rsquo;s separation from service, to the extent required to be delayed in compliance with Code Section&nbsp;409A(a)(2)(B),
such payment or benefit shall not be made or provided to Executive prior to the earlier of (i)&nbsp;the expiration of the six (6)&nbsp;month
period measured from the date of Executive&rsquo;s separation from service, and (ii)&nbsp;the date of Executive&rsquo;s death. On the
first day of the seventh month following the date of Executive&rsquo;s separation from service or, if earlier, on the date of Executive&rsquo;s
death, all payments delayed pursuant to this Section&nbsp;15(a)&nbsp;shall be paid or reimbursed to Executive in a lump sum, and any remaining
payments and benefits due to Executive under this Agreement shall be paid or provided in accordance with the normal payment dates specified
for them herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
the extent any reimbursement of costs and expenses provided for under this Agreement constitutes taxable income to Executive for Federal
income tax purposes, such reimbursements shall be made no later than December&nbsp;31 of the calendar year next following the calendar
year in which the expenses to be reimbursed are incurred. With regard to any provision herein that provides for reimbursement of expenses
or in-kind benefits, except as permitted by Code Section&nbsp;409A, (i)&nbsp;the right to reimbursement or in-kind benefits is not subject
to liquidation or exchange for another benefit, (ii)&nbsp;the amount of expenses eligible for reimbursement, or in-kind benefits, provided
during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable
year. Any tax gross-ups provided for under this Agreement shall in no event be paid to Executive later than the December&nbsp;31 of the
calendar year following the calendar year in which the taxes subject to gross-up are incurred or paid by Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;If
any amount under this Agreement is to be paid in two or more installments, for purposes of Code Section&nbsp;409A each installment shall
be treated as a separate payment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Indemnification</U>.
During Executive&rsquo;s employment, the Company shall maintain directors&rsquo; and officers&rsquo; liability insurance that is
applicable to Executive. The Company shall indemnify Executive and hold Executive harmless from and against any claim, loss or cause
of action arising from or out of Executive&rsquo;s performance prior to or after the Commencement Date (and within the scope of his
employment) as an officer, director or employee of the Company or any of its subsidiaries or other affiliates or predecessors or in
any other capacity, including any fiduciary capacity, in which Executive serves at the Company&rsquo;s request, in each case to the
maximum extent permitted by applicable corporate law and, to the extent more favorable, to the maximum extent permitted under the
Company&rsquo;s Certificate of Incorporation and By-Laws. On the Commencement Date, the Company shall execute and deliver to
Executive an Indemnification Agreement, in the form adopted by the Board, pursuant to which the Company agrees to indemnify
Executive and advance defense costs and expenses. The rights under this Section&nbsp;16 shall in all cases be on terms no less
favorable to Executive than to other senior executives of the Company and shall survive the termination of employment until the
expiration of the applicable statute of limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Executive
Acknowledgement</U>. Executive hereby acknowledges that Executive has read and understands the provisions of this Agreement, that Executive
has been given the opportunity for Executive&rsquo;s legal counsel to review this Agreement, that the provisions of this Agreement are
reasonable, and that Executive has received a copy of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[remainder of page&nbsp;intentionally left blank]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties hereto have caused
this Employment Agreement to be executed as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48%"><B>ROCKWELL MEDICAL,&nbsp;INC.</B></TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ MARK STROBECK</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:&nbsp;Mark Strobeck</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title: President and CEO</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><B>EXECUTIVE</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid">/s/ JESSE NERI</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Jesse Neri</TD>
    <TD>&nbsp;</TD>
    <TD>Date</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<I>Beneficiary</I>&rdquo;
means any individual, trust or other entity named by Executive to receive the payments and benefits payable hereunder in the event
of the death of Executive. Executive may designate a Beneficiary to receive such payments and benefits by completing a form provided
by the Company and delivering it to the General Counsel or Secretary of the Company. Executive may change his designated Beneficiary
at any time (without the consent of any prior Beneficiary) by completing and delivering to the Company a new beneficiary designation
form. If a Beneficiary has not been designated by Executive, or if no designated Beneficiary survives Executive, then the payment
and benefits provided under this Agreement, if any, will be paid to Executive&rsquo;s estate, which shall be deemed to be
Executive&rsquo;s Beneficiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<I>Cause</I>&rdquo;
means: (i)&nbsp;Executive&rsquo;s material breach of this Agreement or any other material policy of the Company, in each instance only
after a written demand to cure such breach is delivered to Executive setting forth in reasonable detail the circumstances of such breach
and Executive fails to cure such breach (if it reasonably can be cured) within the thirty (30) day period following his receipt of such
written notice; (ii)&nbsp;Executive&rsquo;s continued willful neglect of Executive&rsquo;s duties with the Company or willful failure
to comply with an express lawful written directive relating to Executive&rsquo;s duties (other than as a result of Executive&rsquo;s incapacity
due to physical or mental illness), after a written demand for substantial performance is delivered to Executive, which specifically identifies
the manner in which the Company believes that Executive has neglected his duties or failed to comply with a lawful directive and Executive
fails to comply with such written demand within the thirty (30) day period following its receipt; (iii)&nbsp;any material act of dishonesty,
or any act of misappropriation, embezzlement, fraud or similar conduct involving the Company or any of its affiliates; (iv)&nbsp;the conviction
of or the plea of nolo contendere or the equivalent by Executive of a felony or other crime involving moral turpitude; or (v)&nbsp;Executive&rsquo;s
engagement in illegal conduct or gross misconduct which is materially and demonstrably injurious to the Company. No act or failure to
act by Executive shall be considered &ldquo;willful&rdquo; unless it is done or omitted to be done by Executive in bad faith and without
reasonable belief that he was acting in the best interests of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">&ldquo;<I>Change of Control</I>&rdquo; means a &ldquo;Change in Control&rdquo; as defined in the Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<I>Change
of Control Date</I>&rdquo; means any date after the date hereof on which a Change of Control occurs; provided, however, that if a
Change of Control occurs and if Executive&rsquo;s employment with the Company is terminated or an event constituting Good Reason (as
defined below) occurs prior to the Change of Control, and if it is reasonably demonstrated by Executive that such termination or
event: (i)&nbsp;was at the request of a third party who has taken steps reasonably calculated to effect the Change of Control, or
(ii)&nbsp;otherwise arose in connection with or in anticipation of the Change of Control then, for all purposes of this Agreement,
the Change of Control Date shall mean the date immediately prior to the date of such termination or event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<I>Code</I>&rdquo;
means the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<I>Date
of Termination</I>&rdquo; means the date specified in a Notice of Termination pursuant to Section&nbsp;6 hereof, or Executive&rsquo;s
last date as an active employee of the Company before a termination of employment due to death, Disability or other reason, as the case
may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<I>Disability</I>&rdquo;
means a mental or physical condition that renders Executive substantially incapable of performing his duties and obligations under this
Agreement, after taking into account provisions for reasonable accommodation, as determined by a medical doctor (such doctor to be mutually
determined in good faith by the parties) for three or more consecutive months or for a total of six months during any 12 consecutive months;
provided, that during such period the Company shall give Executive at least 30 days&rsquo; written notice that it considers the time period
for disability to be running.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<I>Effective
Period</I>&rdquo; means the period beginning on the Change of Control Date and ending 18 months after the date of the related Change of
Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&ldquo;<I>Good
Reason</I>&rdquo; means, subject to the notice and cure provisions set forth in Section&nbsp;6(b), and unless Executive has
consented in writing thereto, the occurrence of any of the following: (i)&nbsp;the assignment to Executive of any duties materially
inconsistent with Executive&rsquo;s position under this Agreement, including any material change in status, title, authority,
reporting, duties or responsibilities, or other action which results in a material diminution in Executive&rsquo;s authorities,
duties, responsibilities or reporting; (ii)&nbsp;a reduction in Executive&rsquo;s Base Salary by the Company of more than 5%, unless
such reduction is made proportionately in connection with broader salary reductions among all of the Company&rsquo;s executive
officers; (iii)&nbsp;the relocation of Executive&rsquo;s principal work location of more than 30 miles; or (iv)&nbsp;the
Company&rsquo;s material breach of this Agreement or any other material written agreement between the Company and Executive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EMPLOYEE CONFIDENTIALITY, ASSIGNMENT OF INVENTIONS,
NON- INTERFERENCE AND NON-COMPETITION AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following is an agreement (&ldquo;<I>Agreement</I>&rdquo;)
is made as of October&nbsp;16, 2023, between Jesse Neri and Rockwell Medical,&nbsp;Inc., a Delaware corporation (the &ldquo;<I>Company</I>&rdquo;),
and any successor in interest, and me, Jesse Neri, and this Agreement is a material part of the consideration for my Employment Agreement
with the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Job
Title and Responsibility</U>. I understand that my job title with the Company will be SVP, Finance. My job duties and responsibilities
will be those set forth in my Employment Agreement with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Consideration</U>.
I understand that the consideration to me for entering into this Agreement is my Employment Agreement with the Company, and I agree that
this consideration is fully adequate to support this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Proprietary
Information</U>. I acknowledge that the Company is engaged in a continuous program of research, development and production. I also acknowledge
that the Company possesses or has rights to secret, private, confidential information and processes (including processes and information
developed by me during my employment by the Company) which are valuable, special and unique assets of the Company and which have commercial
value in the Company&rsquo;s business (&ldquo;<I>Proprietary Information</I>&rdquo;). Proprietary Information includes, but is not limited
to, information and details regarding the Company&rsquo;s business, trade or business secrets, inventions, intellectual property, systems,
policies, records, reports, manuals, documentation, models, data and data bases, products, processes, operating systems, manufacturing
techniques, research and development techniques and processes, devices, methods, formulas, compositions, compounds, projects, developments,
plans, research, financial data, personnel data, internal business information, strategic and staffing plans and practices, business,
marketing, promotional or sales plans, practices or programs, training practices and programs, costs, rates and pricing structures and
business methods, computer programs and software, customer and supplier identities, information and lists, confidential information regarding
customers and suppliers, and contacts at or knowledge of Company suppliers and customers or of prospective or potential customers and
suppliers of the Company. Excluded from the definition of Proprietary Information is information that is or becomes part of the public
domain, other than through the breach of this Agreement by Executive. For this purpose, information known or available generally within
the trade or industry of the Company or any affiliate shall be deemed to be known or available to the public and not to be Proprietary
Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Obligation
of Confidentiality</U>. I understand and agree that my employment creates a relationship of confidence and trust between the Company
and me with respect to (i)&nbsp;all Proprietary Information, and (ii)&nbsp;the confidential information of others with which the
Company has a business relationship. At all times, both during my employment by the Company and after the termination of my
employment (whether voluntary or involuntary),&nbsp;I will keep in confidence and trust all such information, and I will not use,
reveal, communicate, or disclose any such Proprietary Information or confidential information to anyone or any entity, without the
written consent of the Company, unless I am ordered to make disclosure by a court of competent jurisdiction. Notwithstanding any
other provision in this Agreement or any other agreement, if I make a confidential disclosure of a Company trade secret to a
government agency, government official or an attorney for the purpose of reporting or investigating a suspected violation of law, or
in a court filing under seal,&nbsp;I will not be held liable under this Agreement or any other agreement, or under any federal or
state trade secret law for such a disclosure. Moreover, nothing in this Agreement or any other agreement shall prevent me from
making a confidential disclosure of any other Proprietary Information to a government official, to an attorney as necessary to
obtain legal advice or in a court filing under seal or otherwise as required by law. By signing this Agreement,&nbsp;I agree to
waive my right to recover individual relief based on any claims asserted in such a complaint or charge; provided, however, that
nothing in this Agreement limits my right to receive an award for information I provide to any government agencies that are
authorized to provide monetary or other awards to eligible individuals who come forward with information that leads to an agency
enforcement action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Ownership,
Disclosure and Assignment of Proprietary Information and Inventions</U>. In addition,&nbsp;I hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Ownership
and Assignment</U>. All Proprietary Information is, and shall be, the sole and exclusive property of the Company and its successors and
assigns, and the Company and its successors and assigns shall be the sole and exclusive owner of all Proprietary Information, including,
but not limited to, trade secrets, inventions, patents, trademarks, copyrights, and all other rights in connection with such Proprietary
Information. I agree that I have no rights in Proprietary Information. I hereby assign, and shall assign, to the Company and its successors
and assigns any and all rights, title and interest I may have or acquire in Proprietary Information. Any copyrightable work prepared in
whole or in part by me in the course of my employment shall be deemed &ldquo;a work made for hire&rdquo; under applicable copyright laws,
and the Company and its successors and assigns shall own all of the rights in any copyright.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Return
of Materials and Property</U>. All documents, records, apparatus, equipment, databases, data and information, whether stored in physical
form or by electronic means, and all electronic, computer, intellectual, and physical property (&ldquo;<I>Materials and Property</I>&rdquo;),
whether or not pertaining to Proprietary Information, furnished to me by the Company or produced by me or others in connection with employment,
shall be and remain the sole and exclusive property of the Company. I shall return to the Company all Materials and Property as and when
requested by the Company. Even if the Company does not so request,&nbsp;I shall return all Materials and Property upon termination of
employment by me or by the Company for any reason, and I will not take with me any Materials and Property, or any reproduction thereof,
upon such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Notification</U>.
During the term of my employment and for one (1)&nbsp;year thereafter,&nbsp;I will promptly disclose to the Company, or any persons designated
by it, all improvements, inventions, intellectual property, works of authorship, formulas, ideas, processes, techniques, discoveries,
developments, designs, devices, innovations, know-how and data, and creative works in which copyright and/or unregistered design rights
will subsist in various media (collectively, &ldquo;<I>Inventions</I>&rdquo;), whether or not such Inventions are patentable, which I
make or conceive, contribute to, reduce to practice, or learn, either alone or jointly with others, during the term of my employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Ownership
of Inventions. I agree and acknowledge that all Inventions which I make, conceive, develop, or reduce to practice (in whole or in part,
either alone or jointly with others) at any time during my employment by the Company, and (i)&nbsp;which were created using the equipment,
supplies, facilities or trade secret information of the Company; or (ii)&nbsp;which were developed during the hours for which I was compensated
by the Company; or (iii)&nbsp;which relate, at the time of conception, creation, development or reduction to practice, to the business
of the Company or to its actual or demonstrably anticipated research and development; or (iv)&nbsp;which result from any work performed
by me for the Company, shall be the sole and exclusive property of the Company and its successors and assigns (and to the fullest extent
permitted by law shall be deemed works made for hire), and the Company and its successors and assigns shall be the sole and exclusive
owner of all Inventions, patents, copyrights and all other rights in connection therewith. I hereby assign to the Company any and all
rights I may have or acquire in such Inventions. I agree that any such Invention required to be disclosed under paragraph (c), above,
within one (1)&nbsp;year after the termination of my employment shall be presumed to have been conceived or made during my employment
with the Company and will be assigned to the Company unless and until I prove and establish to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Assistance
and Cooperation</U>. With respect to Inventions described in paragraph (d), above,&nbsp;I will assist the Company in every proper way
(but at the Company&rsquo;s expense) to obtain, and from time to time enforce, patents, copyrights or other rights on these Inventions
in any and all countries and will execute all documents reasonably necessary or appropriate for this purpose. This obligation shall survive
the termination of my employment. In the event that the Company is unable for any reason whatsoever to secure my signature to any document
reasonably necessary or appropriate for any of the foregoing purposes (including renewals, extensions, continuations, divisions or continuations
in part),&nbsp;I hereby irrevocably designate and appoint the Company, and its duly authorized officers and agents, as my agents and attorneys-in-
fact to act for and in my behalf and instead of me, but only for the purpose of executing and filing any such document and doing all other
lawfully permitted acts to accomplish the foregoing purposes with the same legal force and effect as if executed by me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Exempt
Inventions</U>. I understand that this Agreement does not require assignment of an Invention for which no equipment, supplies, facilities,
resources, or trade secret information of the Company was used, and which was developed entirely by me on my own time, unless the invention
relates (i)&nbsp;directly to the business of the Company or (ii)&nbsp;to the Company&rsquo;s actual or demonstrably anticipated research
or development. However,&nbsp;I will disclose to the Company any Inventions I claim are exempt, as required by paragraph (c)&nbsp;above,
in order to permit the Company to determine such issues as may arise. Such disclosure shall be received in confidence by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Prior
Inventions</U>. As a matter of record,&nbsp;I attach hereto as Exhibit&nbsp;I a complete list of all inventions or improvements
relevant to the subject matter of my employment by the Company which have been made or conceived or first reduced to practice by me,
alone or jointly with others, prior to my employment with the Company, that I desire to remove from the operation of this Agreement,
and I covenant that such list is complete. If no such list is attached to this Agreement,&nbsp;I represent that I have no such
inventions and improvements at the time of my signing this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Other
Business Activities</U>. So that the Company may be aware of the extent of any other demands upon my time and attention,&nbsp;I will disclose
to the Company (such disclosure to be held in confidence by the Company) the nature and scope of any other business activity in which
I am or become engaged during the term of my employment. During the term of my employment,&nbsp;I will not engage in any business activity
or employment which is in competition with, or is related to, the Company&rsquo;s business or its actual or demonstrably anticipated research
and development, or that will affect in any manner my ability to perform fully all of my duties and responsibilities for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify"><U>Non-Interference and Non-Solicitation of Employees, Customers and Others</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;During
my employment with the Company and for twelve (12) months after the termination of my employment (whether the termination is by me or
the Company, the &ldquo;<I>Restricted Period</I>&rdquo;),&nbsp;I will not, and will not attempt to directly or indirectly do any one or
more of the following: (i)&nbsp;induce, encourage or solicit any employee, consultant, or independent contractor of the Company to leave
the Company for any reason, unless specifically requested to take such action in writing by the Company; or (ii)&nbsp;employ, retain,
or engage any employee, consultant, or independent contractor of the Company. For purposes of this Section&nbsp;8(a), the terms &ldquo;employee&rdquo;,
 &ldquo;consultant&rdquo; and &ldquo;independent contractor&rdquo; shall include those who served in such capacities within six (6)&nbsp;months
preceding the date of the termination of my employment; provided, that nothing herein shall prevent me from engaging in discussions regarding
employment, or employing, any such employee, consultant or independent contractor if such discussions shall be held as a result of, or
any employment shall be the result of, the response by any such person to a written employment advertisement placed in a publication of
general circulation, general solicitation conducted by executive search firms, employment agencies or other general employment services,
not directed specifically at any such employee, consultant or independent contractor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;During
the Restricted Period,&nbsp;I will not, and will not attempt to, directly or indirectly, solicit, divert, disrupt, interfere with or take
away any Company customer, supplier, agent, vendor, distributor, representative, or other contracting party with the Company that had
such a relationship with the Company during my employment with the Company to a business that is a Competitor of the Company. For purposes
of this Agreement, the term &ldquo;<I>Competitor</I>&rdquo; shall include any company or other entity engaged in developing or commercializing
any one or more of the following: (i)&nbsp;drug products, drug therapies and concentrates/dialysates that target end-stage renal disease
and chronic kidney disease for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis or (ii)&nbsp;any product
or process developed and commercialized, or under development in whole or in part, by the Company during my employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;During
the Restricted Period,&nbsp;I will not, and will not attempt to, directly or indirectly induce any customer, supplier, agent, vendor,
distributor, representative, or other contracting party with the Company that had such a relationship with the Company during my employment
with the Company, to reduce its patronage of the Company or to terminate any written or oral agreement or understanding, or any other
business relationship with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Non-Competition
During and After Employment</U>. During the Restricted Period,&nbsp;I will not directly or indirectly, without the prior written consent
of the Company, maintain a relationship with a Competitor including as an employee, employer, consultant, agent, lender, investor, principal,
partner, stockholder, corporate officer, director, or in any other individual or representative capacity; provided that, nothing in this
Agreement shall prohibit me from being a passive owner of not more than three percent (3%) of the outstanding equity of any entity that
itself or through its affiliates in engaged in various businesses including a business that would be considered a Competitor as long as
I have no involvement with the competitive business. I understand and agree that the restrictions in this paragraph are necessary and
reasonable to protect the legitimate business interests of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Obligations
to Former Employers</U>. I represent that my execution of this Agreement, my employment with the Company, and my performance of my duties
and proposed duties to the Company will not violate any obligations or agreements I have, or may have, with any former employer or any
other third party, including any obligations and agreements requiring me not to compete or to keep confidential any proprietary or confidential
information. I have not entered into, and I will not enter into, any agreement which conflicts with this Agreement or that would, if performed
by me, cause me to breach this Agreement. I further represent that I have no knowledge of any pending or threatened litigation to which
the Company may become a party by virtue of my association with the Company. I further agree to immediately inform the Company of any
such pending or threatened litigation should it come to my attention during the course of my employment. I also represent that I have
provided to the Company for its inspection before I signed this Agreement all confidentiality, non-compete, non- solicitation, and all
other employment-related agreements and obligations to which I am party to which I am bound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Confidential
Information of, and Agreements with, Former Employers</U>. In the course of performing my duties to the Company,&nbsp;I will not utilize
any trade secrets, proprietary or confidential information of or regarding any former employer or business affiliate in violation of any
duty not to disclose or use such information, nor violate any written or oral, express or implied agreement with any former employer or
other third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>United
States Government Obligations</U>. I acknowledge that the Company from time to time may have agreements with other persons or with the
United States Government, or agencies thereof, which impose obligations or restrictions on the Company regarding inventions made during
the course of work under such agreements or regarding the confidential nature of such work. I agree to be bound by all such obligations
and restrictions which are made known to me and to take all reasonable action to assist the Company in discharging the obligations of
the Company under such agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Remedies</U>.
I acknowledge that my failure to comply in all material respects with, or my material breach of, any of the terms and conditions of
this Agreement shall irreparably harm the Company, and that money damages would not adequately compensate the Company for this harm.
Accordingly,&nbsp;I acknowledge that in the event of a threatened or actual material breach by me of any provision of this
Agreement, in addition to any other remedies the Company may have at law, the Company shall be entitled to seek equitable relief in
the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy then
available, without requiring the Company to post any bond. I agree that nothing herein contained shall be construed as prohibiting
the Company from pursuing any other remedies available to it for such threatened or actual breach, including money damages, and I
agree that the Company shall be entitled to recover from me any attorney&rsquo;s fees it incurs in enforcing the terms of this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Not
an Employment Agreement</U>. I acknowledge and agree that this Agreement is not a contract of employment for any specific period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">15.</TD><TD STYLE="text-align: justify"><U>Miscellaneous</U>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Reformation
and Severability</U>. If any provision of this Agreement is held to be invalid or unenforceable under applicable law, such provision shall
be reformed and/or construed, if possible, to be enforceable under applicable law; otherwise, such provision shall be excluded from this
Agreement and the balance of the Agreement shall remain fully enforceable and valid in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>No
Waiver</U>. No delay or omission by the Company in exercising any right hereunder will operate as a waiver of that or any other right.
A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to
or waiver of any right on any other occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Reassignment</U>.
I expressly consent to be bound by the provisions of this Agreement for the benefit of the Company or any subsidiary or affiliate thereof
to whose employment I may be transferred, without the necessity that this Agreement be reassigned at the time of such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Applicable
Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware (but not the law or principles
of conflict of laws). The parties submit to the exclusive jurisdiction of the state or federal courts of Delaware for all disputes arising
out of or relating to this Agreement, and hereby waive, and agree not to assert, in any action, suit, or proceeding between the parties
arising out of or relating to this Agreement that the action, suit, or proceeding may not be brought or is not maintainable in such courts,
that this Agreement may not be enforced by such courts, that the action, suit, or proceeding is brought in an inconvenient forum, that
the venue of the action, suit, or proceeding is improper, or that the action, suit, or proceeding, if brought in Delaware state court,
may be removed to federal courts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Effective
Date</U>. This Agreement shall be effective as of the date of my Employment Agreement with the Company, shall be binding upon me, my heirs,
executors, assigns and administrators, and shall inure to the benefit of the Company and its successors and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Entire
Agreement</U>. This Agreement, together with my Employment Agreement with the Company, contains the entire agreement of the parties relating
to the subject matter herein, and may not be waived, changed, extended or discharged except by an agreement in writing signed by both
parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<U>Acknowledgement</U>.
I acknowledge and agree that I have fully read and that I understand all of the terms and provisions of this Agreement, that I have had
the opportunity to consult with an attorney and to discuss this Agreement with an attorney, that I have had any questions regarding the
effect of this Agreement or the meaning of its terms answered to my satisfaction, and, intending to be legally bound hereby,&nbsp;I freely
and voluntarily sign this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>ROCKWELL MEDICAL,&nbsp;INC.</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 45%">/s/ MARK STROBECK</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:&nbsp;&nbsp;</TD>
    <TD>Mark Strobeck, Ph.D.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>President&nbsp;&amp; CEO</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><B>EXECUTIVE</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">/s/ JESSE NERI</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">October&nbsp;2, 2023</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Jesse Neri</TD>
    <TD>&nbsp;</TD>
    <TD>Date</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;I</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
following is a complete list of all inventions or improvements (&ldquo;<I>Intellectual Property&rdquo;) </I>relevant to my employment
by Rockwell Medical,&nbsp;Inc. (the &ldquo;<I>Company</I>&rdquo;) that have been made or conceived or first reduced to practice by me,
alone or jointly with others, prior to my employment by the Company that I desire to remove from the operation of the Employee Confidentiality,
Assignment of Inventions, Non-Interference and Non-Competition Agreement between me and the Company (the &ldquo;<I>Employee Agreement</I>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD><TD STYLE="text-align: justify">No Intellectual Property.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Any and all Intellectual Property regarding:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Additional sheets attached.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;I
propose to bring to my employment the following materials and documents of a former employer or materials and documents created by me
and/or others during any previous employment (&ldquo;<I>Materials</I>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD><TD STYLE="text-align: justify">No Materials.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Materials:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Additional sheets attached.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;I
acknowledge and agree that the Materials set forth above are being provided by me in accordance with the representations set forth in
Section&nbsp;6 of the Employee Agreement between me and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 48%">/s/ JESSE NERI</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 48%">October&nbsp;2, 2023</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Jesse Neri</TD>
    <TD>&nbsp;</TD>
    <TD>Date</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SEPARATION AND RELEASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Separation and Release
Agreement (the &ldquo;Agreement&rdquo;) is made between Rockwell Medical,&nbsp;Inc., a Delaware corporation (the &ldquo;Company&rdquo;),
and Jesse Neri (&ldquo;Executive&rdquo;, and together with the Company, the &ldquo;Parties,&rdquo; and each a &ldquo;Party&rdquo;). Capitalized
terms used but not defined herein shall have the meanings ascribed thereto in the Employment Agreement, dated as of October&nbsp;__, 2023,
by and between the Company and Executive (the &ldquo;Employment Agreement&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Executive&rsquo;s
employment ended, effective [&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;, 20 ] (the &ldquo;Separation Date&rdquo;). Effective as of the Separation
Date, Executive automatically resigned from any appointed or elected positions with any Released Party (as defined below), and Executive
will cooperate with the Company to effectuate such resignations. The Company has provided Executive his accrued base salary through the
Separation Date, and Executive is not owed any additional amount from any Released Party except as set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Provided
this Agreement has become effective, that Executive&rsquo;s representations set forth herein are accurate, and that Executive continues
to abide by his obligations to the Company, the Company will provide Executive with the severance amounts and benefits set forth in Section&nbsp;5(b)&nbsp;of
the Employment Agreement (collectively, the &ldquo;Severance Benefits&rdquo;) in accordance with the terms of the Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Executive,
on behalf of himself, his heirs, successors, assigns, and any individual or entity that could assert a claim through him or on his
behalf relating to Executive&rsquo;s employment or termination of employment with the Company, fully and forever releases, acquits
and discharges the &ldquo;Released Parties&rdquo; (defined as the Company, all of its past and present affiliates, parent companies,
subsidiaries, investors, predecessors, successors, assigns, and related companies and entities, and all of their past and present
shareholders, members, managers, partners, directors, officers, supervisors, trustees, employees, attorneys, persons and agents and
all other persons and entities acting in connection with any of them) from and for all manner of claims, allegations, suits,
charges, administrative actions, litigation and/or causes of action of any type, based upon any fact or set of facts, known or
unknown, existing from the beginning of time through the date this Agreement is signed by him (the &ldquo;Released Claim(s)&rdquo;).
Without limitation and for illustration purposes only, the Released Claims include claims for or relating to: monetary damages and
relief and/or recovery of every type; wrongful discharge; breach of express or implied contract, including regarding the Employment
Agreement; any severance policy or plan; any incentive equity plan, policy or agreement; attorneys&rsquo; fees and costs;
retaliation, discrimination and/or harassment related to any protected characteristic or activity; Title VII of the Civil Rights
Act, the Age Discrimination in Employment (&ldquo;ADEA&rdquo;), the Older Workers Benefit Protection Act, the Americans with
Disabilities Act, and the Employee Retirement Income Security Act; and all other federal, state, common or local statutes,
ordinances and laws. Notwithstanding the foregoing, Executive is not prohibited from making or asserting: (i)&nbsp;Executive&rsquo;s
rights under this Agreement and any claims arising from the breach of this Agreement, the Employment Agreement or any equity award
agreement by the Company, including any claim for breach of Company&rsquo;s obligation to make the payments described in
Section&nbsp;2 above; (ii)&nbsp;Executive&rsquo;s rights, if any, to indemnity pursuant to the Company&rsquo;s articles, bylaws, or
any indemnification agreement between the Company and Executive and/or to the protections of any director&rsquo; and officers&rsquo;
liability policies of the Company and (iii)&nbsp;if Executive owns an equity interest in the Company, him rights as an equity
owner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;The
Parties intend that the general release by Executive will be construed as broadly as possible. Executive agrees not to commence or pursue
any legal action regarding any Released Claims, provided that this Agreement does not limit his right, where applicable, to file or participate
in an investigative proceeding of any federal, state or local governmental agency. To the extent permitted by law, Executive agrees that
if such an administrative claim is made, he shall not be entitled to recovery of individual monetary relief or other individual remedies,
provided that nothing in this Agreement limits his right to participate in the Securities and Exchange Commission&rsquo;s (&ldquo;SEC&rdquo;)
whistleblower program and receive a whistleblower&rsquo;s award thereunder. The Parties further acknowledge that the Company and its affiliates
are not releasing any claims against Executive or any other individual, and all rights as to such claims are reserved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Executive
represents and warrants that: (a)&nbsp;he has returned all Company property, information and files in his possession, without retaining
copies of same; (b)&nbsp;he has complied with the Employee Confidentiality, Assignment of Inventions, Non-Interference and Non- Competition
Agreement between Executive and the Company dated as of October&nbsp;__, 2023 (the &ldquo;Restrictive Covenant Agreement&rdquo;); and
(c)&nbsp;he has not assigned any Released Claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Executive
will cooperate with the Company in providing information with respect to all reports required to be filed by the Company with the SEC
as they relate to required information with respect to him. Executive acknowledges and agrees that the Company may be required to file
a copy of this Agreement with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Executive
acknowledges that he remains bound by, and will comply in all material respects with, his post-employment obligations to the Company,
including but not limited to those set forth in the Employment Agreement and the Restrictive Covenant Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Executive
acknowledges and agrees that pursuant to the requirements of Section&nbsp;954 of the Dodd-Frank Wall Street Reform and Consumer Protection
Act (&ldquo;Section&nbsp;954&rdquo;), certain payments received by Executive may be subject to &ldquo;clawback&rdquo; in the event the
Company is required to prepare an accounting restatement of its applicable financial statements due to the Company&rsquo;s material noncompliance
with applicable financial reporting requirements. Executive agrees to promptly return to the Company the amount of any compensation paid
to him that is required to be forfeited in accordance with Section&nbsp;954.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Executive
acknowledges that the Company&rsquo;s promises set forth throughout this Agreement would not be provided unless Executive executed this
Agreement and are each separate and adequate consideration for this Agreement, including Executive&rsquo;s release of claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
the fullest extent permitted by law, and except as to statements made in legal, administrative or arbitral proceedings in disputes
between Executive and the Company and truthful testimony, Executive agrees that he will not make public statements that defame,
disparage or otherwise publicly speak of the Company or its present or former officers or members of the Board and/or its products
or services in a false or misleading manner, including but not limited to through any media, social media, Facebook, Twitter or
similar mechanism.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;To
the fullest extent permitted by law and at the sole expense of the Company, Executive agrees to reasonably cooperate with the Released
Parties in any internal investigation, any administrative, regulatory or judicial proceeding or any dispute with a third party that he
had knowledge of while employed by or providing services to the Company. Executive&rsquo;s cooperation may include being available to
the Company upon reasonable notice and subject to Executive&rsquo;s personal and professional commitments, for interviews and factual
investigations, appearing at the Company&rsquo;s request to give testimony without requiring service of a subpoena or other legal process,
and turning over to the Company all relevant documents which are or may come into Executive&rsquo;s possession. If Executive is served
with a subpoena or is required by court order or otherwise to testify or produce documents in any type of proceeding involving the Company
or its affiliates, he must advise the Company within ten (10)&nbsp;days of same and reasonably cooperate with the Company in objecting
to such request and/or seeking confidentiality protections.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement does not constitute an admission by the Company that any action it took with respect to Executive was wrongful, unlawful or
in violation of any local, state, or federal act, statute, or constitution, or susceptible of inflicting any damages or injury on Executive,
and the Company specifically denies any such wrongdoing or violation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;In
addition to any other legal and/or equitable remedies, if Executive materially breaches any material provision of this Agreement, the
Employment Agreement, the Restrictive Covenant Agreement, or any other contractual or legal obligation Executive owes to the Company,
then the Company may cease paying and/or providing the Severance Benefits and Executive will be required to repay and/or forfeit any Severance
Benefits received through the date of such breach or discovery of the inaccuracy of his representations, provided that Executive may retain
$1,000 of such payments. The exercise of such remedies will not affect the validity of the release and other obligations of Executive
as set forth in this Agreement or otherwise, nor will it limit the other legal and/or equitable remedies otherwise available to any Released
Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement and the rights and obligations of the parties hereunder will be governed by, and construed and enforced in accordance with,
the laws of the state of Delaware, excluding any such laws that direct the application of the laws of any other jurisdiction. The Released
Parties are intended third party beneficiaries of Executive&rsquo;s obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement will be enforceable to the fullest extent permitted by law. If any provision is held to be unenforceable, then such provision
will be construed or revised in a manner so as to permit its enforceability to the fullest extent permitted by applicable law. If such
provision cannot be reformed in that manner, such provision will be deemed to be severed from this Agreement, but every other provision
of this Agreement will remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">16.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement may not be amended, modified, waived or terminated except in a writing signed by Executive and the Company&rsquo;s
signatory to this Agreement or his successor. Further, the waiver by a party of a breach of any provision of this Agreement by the
other will not operate or be construed as a waiver of any subsequent breach of the same or other provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">17.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Except
as otherwise provided herein, this Agreement will be binding upon and inure to the benefit of the parties&rsquo; respective successors,
permitted assigns and transferees, personal representatives, heirs and estates, as the case may be; provided, however, that Executive&rsquo;s
rights and obligations under this Agreement may not be assigned without the prior written consent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">18.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Executive
has had 21 calendar days to review and sign this Agreement and is advised to consult with an attorney of his choice before signing this
Agreement, which includes a release of potential claims under the ADEA. Executive understands that he may use as much of this 21-day period
as he wishes prior to signing. Changes to the Agreement, whether material or immaterial, will not restart the review period. Executive
may expressly and voluntarily waive any part or all of the 21-day review period by signing and returning this Agreement prior to the expiration
of the review period. Executive has the right to revoke his release of any and all ADEA claims by informing the Company of such revocation
within seven calendar days following his execution of this Agreement (the &ldquo;Revocation Period&rdquo;); for the avoidance of doubt,
no claims other than those arising under ADEA may be revoked during the Revocation Period. Any such revocation must be in writing and
delivered to the Company in care of its signatory to this Agreement or his successor. This Agreement will become effective upon execution
by Executive with respect to all claims other than those arising under ADEA, and will only become effective with respect to the release
of ADEA claims if the Revocation Period has expired without any revocation having been delivered in writing to the Company within the
Revocation Period. In the event that Executive revokes this Agreement with respect to ADEA claims, the Company shall make a single payment
of $1,000, at which point Executive will be entitled to no further payments or severance benefits hereunder or under the Employment Agreement.
Upon the expiration of the Revocation Period without the revocation of the ADEA claims, this Agreement shall be deemed to have become
 &ldquo;final, binding and irrevocable,&rdquo; as set forth in Section&nbsp;5(b)&nbsp;of the Employment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">19.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement reflects the entire agreement of the parties relative to the subject matter hereof, and supersedes all prior, contemporaneous,
oral or written understandings, agreements, statements, representations or promises regarding the subject matter hereof, provided that
this Agreement does not supersede or modify the Employment Agreement, the Restrictive Covenant Agreement and those agreements pertaining
to Executive&rsquo;s equity holdings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">20.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;This
Agreement may be signed in counterparts, and when this Agreement has been signed by all parties, each counterpart shall constitute an
original, notwithstanding that fewer than all of the parties&rsquo; signatures appear on any one counterpart. An electronic signature
transmitted by facsimile or other electronic means shall be deemed to be an original.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>[Signature Page&nbsp;Follows]</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The parties hereto confirm their agreement by the signatures
shown below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Rockwell Medical,&nbsp;Inc.</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name:&nbsp;&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Jesse Neri</TD>
    <TD>&nbsp;</TD>
    <TD>Date</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 28; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rmti-20241210.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWayP6bOdzZR+yYkxtmB4bQla7yQglBBavy+6U6G20bcN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:rmti="http://rockwellmed.com/20241210" elementFormDefault="qualified" targetNamespace="http://rockwellmed.com/20241210">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://rockwellmed.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="rmti-20241210_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="rmti-20241210_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rmti-20241210_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rmti-20241210_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://rockwellmed.com/role/Cover" xlink:href="rmti-20241210.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://rockwellmed.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46062822087968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 10, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 10,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Rockwell
Medical, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001041024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">38-3317208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">30142
S. Wixom Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wixom<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">48393<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">960-9009<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RMTI<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;
M 4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " !6AXQ9EXJ[',     3 @
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MY68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B?
M:ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G6
M0VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_
M,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    " !6AXQ9)!Z;HJT   #X 0
M&@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I
M0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LID
MR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\
M./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6
M?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ 5H>,6660>9(9 0
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M<',O87!P+GAM;%!+ 0(4 Q0    ( %:'C%GYT'*<[@   "L"   1
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M96QS+RYR96QS4$L! A0#%     @ 5H>,6:K$(A8S 0  (@(   \
M     ( !1Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %:'C%DD'INB
MK0   /@!   :              "  :<1  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( %:'C%EED'F2&0$  ,\#   3
M  "  8P2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  -83
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2430838d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://rockwellmed.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>rmti-20241210.xsd</File>
    <File>rmti-20241210_lab.xml</File>
    <File>rmti-20241210_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2430838d1_8k.htm">tm2430838d1_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2430838d1_8k.htm": {
   "nsprefix": "rmti",
   "nsuri": "http://rockwellmed.com/20241210",
   "dts": {
    "schema": {
     "local": [
      "rmti-20241210.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rmti-20241210_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rmti-20241210_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tm2430838d1_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://rockwellmed.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2024-12-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2430838d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-12-10",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2430838d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://rockwellmed.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001104659-24-128064-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-24-128064-xbrl.zip
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M42\3'7PO6 8-#Q.-/"M8T.8Y^MV$F:;%C*+N6-BP7JE6RCG4&D:-ID;PG_V
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M'7@?&QR,CLY*;FJ(L_E/YH-+.P?\,-K%!K'N8@M3G]D<YO$CL)5<>LP7-ZP
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M_^9'*_PT<]$L87 5QU0Q7#&;F(X]*H H66@=\!P:O!IA><07S@I7E")!4A@
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MBQX;[>UIRNBG-\?_"!,U$AS8?S(0'7B.WTVJF@2W_=WK@LR7:)]>WM 1G](
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M;*GOAWP^;Z8,[F*"6,QYGEUP@+;4;"\-2SVTO$P1&81_QO^K6:.FH5&;R.N
M<^DD7#PD\CHIC)DHVUCR 8CB<=PGR0MLF$8'3!(A:ZQED-0:JS1I"C8[-214
MT,W0SPDG'E]&/>T?FPC:RGXAYM&;(!./HCEHJ@(Y'2R+AGRG>4,W^?'P0'X<
MFKQ*YUO=0D")7[9"6 '2)KQ&'OJMAO[FU]@D&7UN5G@[(IE4V+WJ>R.U5'L+
M*5<G0"Q*RBMTOOM?$4?+LF!G8;&LFR5F%L:<61@W()KFTSKAJ/TI;=L:9H D
MZ4PPEBP@&&N9^?!NC#GVD'2T0.;-DC?@TYF3+0A;#SN#1FVGT.XS&!*(%+EA
M#6[1WEDPUA^]B2=,S9,US^3OTO2>,VN[G]?YNJ_< =IGO9'?6#Z;Q<]X]+HJ
ME\V@RM <!Z-(.-9=*FJEZ^D@M 2[%A(" F.5)?4>K-<)GHTYD&B6O9IE/^SD
MI#DC9<$:"6>'KX?$\Z#0HHUTE'X^Z!CJHJ59I8.H&@;A[@+;]NFS;R_=A[%"
M9DK>Y(+6Z::F3N3Q V]W436@HG&"@M/*<$H>N=N=\G6+(BG]+#0;\59:GU9)
MT0P&ZH[>*P866?&SG*2*40C&+C=WTV&A4TVWJB25K$!?BH960U^,JM@\,*OC
M+X7-H''B1/ZN"1\&GF;LA;(:A6G?KA8P,3$8!#L4NLNGF"3_)5+J4712!7N,
MQ7*:<2:\#(85=]#0<SI9FR#152D3P: $MP75(<$V'5(; Q/!N9-JKTXTB9YA
M+E;.TWKQ6%PM6 [^IL)Y&8]PK.ZPM-HN=?+D9?1^P<;!CWBNVD<OHW\DQ1)_
MOM',RI6PP_JTE,S#9-'0V,R_ BSPRXA+5@ 1DSF[&CA8(+U]7^GITV_= @UZ
M4T^__W9-/8TW^V;>7T8GJP4-\( ,M#Q]&;U+YIFLS;L*,_XD2.J8N_"7=6]_
M^NU@-9(_9-\U>\A9?551SU^J\G0/VAV@%&PLB,D_U\"6B!%PX(O?$$#:E:Z<
MO/*E<B<,-F2+'\P1TQ1XRD?H.5:!3Q[OOX@P-#$\W,@^0%MVE#)^%T++/G$T
MZ8)#=2:C9FSXW."C%-2QH:+%UE5\,#K: $XD H87B&TLD(YIM6B=3F%UR?;/
MDI/Q]R0.?\-FZ#&J%&"'BNZ0K2@[\9/SPF1N:6K76"QB\B#"RC@;H"(LG(<^
M9*F;. @W\$*RO5M%OU5YZ4RBP7"^9^G1YJ@6QL<BLR\]@U6Y7.#'/SU#! 3W
MU&+(P("F*R46BB@KN5OK'%6^"+$(TD[&BB/35,*QN3T4,"$;-D$7\"A;;,*E
M9 H<2/-=TDR3_XWJ)7ETLFTZQT@F/#Q( (OJ0O Y8BAE@H@YL@T(-"UJY)2M
MH<W@M*)J,(_RIS6?%DY#.2Q@%+]*+R8KL-7RQ!1I<1T ?UE"!]54(T7[+^(_
M/7M\^4W( MB\ AWJO&[@OR^172ES!)V3V@-A&93J*;9CKQRN9Q*.1["$\W()
MJULR-18\RZ_U%@:CQ'3A%0Z>NPY1YJ\&&?=5%(8G0F3N>-2141T'WW^BW=5Y
MTV#8EVU-;.C.UHS6[$P:QM9;\WY(QVL6CYY[?B13[&OH7F1WDS\>^$KLMB %
ML\>(<+=NO,W[=0L6G6Q"J#AX]?#^Z#IQ<0@1,RZ_HMSA^4.>RP[B0A@R L\B
M%PO0(26>Q&+;)1HT7BYSSB]QA2\)*++Z>=D_2VL]:+L.LO?+RDO1T[PD;5,A
M+HK5X>^43W;#0IC,6FI1UU 3GWS@[^.17&#.=*#O[)@$6-ISANU2(B:RYQW7
MH0V#@[[3F%PE="Z-R%Z(/%RPM9Q$LC?)S-@(]%7>)[=:8.F*G77YY*]<G-PX
M+#W(LXU'6XD2A>,.&/BNMB++3.K$6"<:G1:]YA6L--'.6984[5D<X9O)9@/^
M@91T+C#S[Q_O?U;J@:Q-'^TJYX%!F)I0=[%:ER,>""?Q04-6QPRV@3T0@G?X
M.#?D/4OB2<ZXA(1L3JA3>LY_[;UN??ZCK)#2..US%KC)A@1NZZ6&NC5'%82L
M$%PRX4%\V3S))0;'B&Y>'\E_=9:!+O57X9X<E!O#=OXC2;U:VJN?E">/R<!;
M-9KFS 79Z>=1/YP$!9)\=2RE&F0RLGRN$ZSS"GDZ-B4-! ?Q=;*DL=8 NZPQ
MIA]%] H9A"K#JJ1]GM(NR W NRKU:7J62IKC-8E6ZQKQ8[EHH9L_ZH0'@CR/
M/S<8P@J>,ANKM'TK=;1AT^.3>$@)'<3"I# !8<$\D"^R_]A^V!W>Q-O%3)\^
MA$=O-SSZ]"$\>E=.S%7$?G938O]CEL\GR[K1VEJ2/ :!38(-EG[6='D! ,];
MMF=532=!<^;I,JCPRO1.27F2[&.QO6PW@WJ[Y:CCD3&9>T0[?6A/;;ZC4\[9
M*14U(XN'A+X4OZ\--:PC]OEB2?C[#:9[MC68[B2LI.Z@F1_ =%<X_B=^17NW
M1 ;A9]34PY3VY]S'Q5BH])^K"@D.G+0X>I,E+1OK;ZRCHVMS5\V7V\X,')>"
M3I/Z2X8?=P@#-J+SURU=W'G.Y4N']'P>UH(&XM>2-#1XF(A6&T3N+WLP\DN=
M"(Q]6;(+$<+S2537'.#Q"!J*I&EA%5\Z.2RODY6!CS@\E:!H2()?:%K$0X8N
MV7TER[QEER:.!*+&0!=[F\24 HR^OPQ=ED/]B .Y?S-=S( ;X>*:*U-6'8!6
M$5,TKKL%[YFQ>$&X'5>D8=V924:NB$TFE99ICO:_; )VU1'QMQLR%>HM  CU
MI7GC4*8T+T5R\;6SK-Q,N-L<]A1IM-Y9GRYY(PT<)E0RMSBUMG(AJ&JW^2F:
MCUK*Y*641G)0"ZF!,87@"!+C#Z[VQ:0WNGE?PYCI;Z> .R^.=GXWH5%01DDN
MD*VW8C5<680(P9YB?ETEALW]26[;XQ^16C.!VT26%]%[BF;#=U!YM%A4C<;O
M'-1,KML55D@),UD3DB?HC)R&X#CW.5[PNM?\N@-^71#0D'.+TIPBJTUR3S-S
MLR5";LB$(3^TT!#&&TVZ^<J5C5!3JEYGN!;%^XAZZ5/\+!_)D5R*VK.D+G)A
MJ+)E0HAV[.SK#QQC8+$PQ$BS?M-)A8UY) =&R(K. [Z.G,,S# 5#:N\K/_0W
MCDG99'49I6PMKT#!0+%[ZEI)5&;N_&U4A(CR&O5MLB$NS"4R@$-.GOTPM"-V
M\D?9HS@<ZB[ODU5W&+Z]T*TFQ(>,1\;PX*Q(!VMC-!XFJ*,]<5!B$PNT:>3!
ML!PM-?)J3094OQPRQT2LB$X6,0SM5YF<%DD^;X9)6 8H5PZ9,5*((D%?9[U(
M)D+B>K!0.?J>)12EQ0PSLE3'(=*#M'G.U723W$C]:937=79>20))2P>>:@A6
M*CC6"9@="]RO:%!<*YEC'7"2F5)KW3@C&>90S-,DZH>LE3#2V;5+;I!>]6MW
M"0Y@]W9PWIP^O,B*<PCV)[O1G#[MK+F\!$%AW\K1^-*O,9)GYR4)\**P):.=
MV(C8*Y>4'D4-3L<21:!VF8=VH'['5!C7$I%+_8_:N(U[NOD33%L>[P?>T+YJ
M7I^A8JR*]^UV8B10R6_??!B%$=$_C8'];JJ^PE,C:ON/'/4=&K0F@OFP%OH8
M]4DX94!75$NR91C,-('EQJ. 2V/0#-.L(,=IFC5IG4\\5G&2>E [UH((*AB\
M>213I(:ZZ,YG+HY@RS0$(EGL.\V7:LK'Y^U2*RF81=IIV!;(GA19.4VDS$(1
M[YTEDVT+&Z8JT\%5&X\NF=BP5J.LK$'%"O&O"3D^]4KI3(V_*Z5/P?CN,"'W
M=AF:[Q\R-+>;H?G^(4-S5T[,[44()/LN6K>KV6)(6:=+2,XIS-M ,EV/ 6EL
MX:)"?OCLD#QIG$7V!=[/RWRR!/W.%*4Z'TEHEBD3<@J58<J1L_T?7CP+.(_?
MO_YX$"+1-F5F0AUHU )Y$'O5;&]!+CB].:T:K?'B;X&D[GY%S$2CN)71*X-@
M4L.XL!;*D@A9GH>/Z12*,JZ=$<Y]TT10K!UKB$;E(&]>YBJHFWY&3J7'NB%^
MOJ6]Y0">5(%F_0@<PW-\!(]!*X(LL\9!REU C_W*A&]@"=*:3[TG\/QK.W"?
M.LU7 KN!/9:-=L,UA.2P["XH-Q[IW_Y@4"XX9'(>>V$KKYB1Y04-DJ'DU;D:
MW%;DC$<B<PR=IPEA^>-OUH?4S%TA]Z\^(PCUV>A;*"02<S#'HR%/HO\=DQ %
MSRE@=7%QL\7_;')0D 1A(:LF8.S";./1LB#C%O=X03 34&M<6<Y+?/N].&GG
MUW30WH7GI$/.W%5J3& DGJBK;'%42>$ANSJ9*_D*!MXV'G45+(=(6BG-Y[WO
M0B &!.E$/0^\.:MJN )TGT15=CTJ?1TUC0\^8;HT'!SPN>@ .ZXT+WC#P1-:
MJ%X:ASZ5GB+E%EF=53,-G V7H%@=ZA.F;=)-GEX:CU(6A$FO1@3_UH_J29SA
MO!ZY4^HP.F_-SU;=E]JQ&X<S!Q$0:9-4RAHJA"4Z%*8O6J9#Z)RJL$3;G?1R
M[\+P"%Y/_/BR +9W#CTN?F/G=D+"@UM+PXQ&G-Q"G/&KAN6PD-\,S-G)=[="
MYIST@_0#WN?7>[AOQM/[E37!>+2_3? ><(YB.5^08IE+29'!-0018I]P(8[F
M,%F83L;85S,N;X+BG"@-./UAFI/C8!5SN9Q/))O(H_+R,DGCV"6\TQM$P:"W
M'0_ZD.56I:0(&4+R]/FS.QPTNPV7Y)JV1"Y<6IT,PK[2^P=:VPI[+9D3CK7!
MW %GV#UJ)Y,$)#L.#HIFO!R3D2%+\;,17/21MTN&\WO:8#?DTAR/!L@TKZ2B
MA+O3^6 T1W.;MQY0@1PC9T.$K)^\3I=SF*NIZ<4B877N,R.ZI7>_=)&IP"]&
M+GS6R7,,WY,W;FC(4'CQ?+1]"AF$MLK6#%J#ZY(USNO36BEK!6O+40!\2*ON
M!E7!$MF9:^8T&(]T[#(#]G9GY3?$\07$T)QP9M9,RAT6$-M%U9\]1-5O-ZK^
M["&J?E=.S"W$'HZ#9GY7B9B+L\R![K@73=+(L.:KG?.Q%GK!_I+?E"Z0N%\\
MDB[5[=*U6#_JI@/K_T[H/-UU3,^W$CJ_PVIH^T-U76=J75CO&B"I?SCX[0+?
M-(XMD:CKHN/7 >3D,%K0>4FB=AX;29'/6@%@#!EQ<@9-\\Y.TD!![.'<-%X#
M/#FJ[@/'HP/%U9K /%_@!\P]1&T8X]\JU"X)%%B%4]LLM8,-O3>!\?/K<O>^
M=&"\?P36ALG'(\_#-U0*-CQWU0AW]&\$N(<!:%>.<*>!^O@C 6Z/N/FN1;B_
MZD#DI?6!S[>N#WPG^R>4QP^U@5<$GX*&X5HJT"Y+ 7A<(//YL@2=MT*/QZ/!
MI31&A?9Z2= _6)'7I_2"<DB9!G)@__&CZ&=T,5G6J!09Z 89!V;ZF@UEK77N
M:PR(N>D2HQ*,(QP_.C0EO4$&B,:$&<K73(@O"%2I-3$>!;Z#O<? O!6:;HJ(
MAJ=*WK=I_N..XZ)C9[M_63L8I^-_EUHQPU6/()%M2!X&\QS2!>")E(L V)!9
M9&D^R].@ L5IK1Y=#&PHCE_#X JZQH2&ODO4QAANXSH8^-V"LS;1FAD0^*N'
M$P3[&/NO!43B%& O"DT.FSE7.!>.]LE]8%-%9D*F; ]Y+6QT;G2FW(/"T\A<
M>E^W%76S538'/>GEK8F_9E)HHFAM::JMQFU73FFO '?G*9,M89D&SQZX(PU:
M&GV7N+O&<*U&V-)8NZ[:3N#&)$E2MM^J>=XXZ\Z)W""JSG:97V 3^D?>V*W_
M1&/:0SDM3KV)!TB"%:O'#9RJNN;X;U!R S(HUS76CH(>O^']4SK0(*$4>-4:
MX=69*]]*XW?U>CK3P=9>8/P1TRR9%F1ZCD?2*7J!HA93:+/IQ4RC+B<1$S.8
MP(*=J@APSGGWJV\Z;PCEN1=PN,,'>;OH]O.'Z/;M1K>?/T2W[\J)&51]W[SZ
MTZ.;T'(.&/269/%I8IOSODGF"!-TJ7M\76>+_$A:SN5NR%:^S^#G7",K(=M;
MF1B"Y3[T-=P070\'4TU;;8WI>8K8Z[J(<6[H'4EZ0&WX)@I1U% L)C@<KQ\V
MU[EO/>[.5$E8&3X)*]HUI M*8Q=8V])S!2'.9=&R%FBR8K873D+H1R6E/U$"
M*W33]! _^&/Q@Q=;QP^P#\G0^Y#427I&A@PV)O;B2?+[0Q3AJE$$9@!52IF0
M2*:3&>C@Z&/C8(IMF7N<H1[ZQ+99TT,>2S@\M@>=CLXT1_Q]LM2R48]2 E:O
MB?+3'W=[W7*D%2W'^59J-@H*9LF^;!+1T$D0"-(EJ*8,X@U/7CS^,T36D]V=
M@UW'SC S0<TIFZQ5;6/H=O2^H[)CNM?ZC9<Z28)NK-?K:0MHRUK<CFTTEDS%
MJD\*%\>TFF)=7/7%;K3C\U9_2)2.RV/'$.Q,G\P]D[/5)K]'^9QY.UAEA-T&
M?_CA!^?M3#.S,*8[*G>DS6C,MK4J4]*9,+3IA6'1V]X[ UF]T_DK.@96IS+I
MRA"G9-WVS<PM9%X=\[O]-HJP.0746@ 4-<MJU;BJ%MR<^3)F31I8T4#)DB1E
MTFI_*=%-,JH/9L6"L(@L/7.A=GY?9A!TW**NBI2Q-UI4M4\4[D ^YND.E-3K
M$F ^P3;6"[5Q9Y!]J@;9)'4F_+X\@QYQ4_@.*;SF3)W#Y_^<34&6'$O*21I@
M5BDCICA]1XN:-7;O:P&V@:K)VT&.E$VO.'*:DXU#WW:8,CZY'=>OK"]OA_DH
M^KO,K3.2&-# AH=(E!XAE<;'NBT*^"R%)^WQ#P?#T />93!5BEQ3[KC*3@F=
M(VDQP5>RR/<N-M*6\8F-+;>PAM..:U[L;6':8<R%+8F5IK5D'$ON^"TX,V.;
M\=MW%3,^66T>A\OM3FU["JQRD/&L7,62H2/J/CS:^MDN#>PGN?_(\TT3TNZQ
M]$D.S%GN;'!PN]G'V<@[[S,#W"RK<@\00X0@IPCNBL0*3%[#?[;CM2Q%!%QG
ML;>A?-&]JUL2)$*\)WM#C/P1RJGR4O'0YQB4*+Y\;E:.,2P.^$JF42F!&5)Z
M5::)2?H(;;3:'Z3MA811WN&(S!T(K0+48"P)S;CZSJ0YMFNM!9_6B\5LTRSG
MKI00723:O&!V6<C2NL[/>?.;KA'^JV,O'\MO7=/C 5.SR'A^2(&2C5/5C6UA
MJUQZ<#5XVR^6DX([U:?8Z%($6L]=$D$.^:(U)6&>&G"=.,@<I"7R*F4VT *:
MU_Q,KPFM)J^/J$E%2 (#8F2Y8&5--Y+N  N^S"$:B]AZUD%XC(FL[C_K).>M
MTI?LO$O&<Y[>TRNJ 6N)6#/)2&)$46PG5@LH:3#*+*0,@0*?":?E440;*YIE
M2K!K.81U2)U9<M[ I"*GV_0[Z3VR7(7[Q?)MK7^>%OI:<,_@#-YA";%=S/9/
M#S';VXW9_NDA9GM73LR:F.T/-QRS_85<;U*E/V<V4)NP%0,\@Q5'EA5=(78Y
M$\^6M(OIY@%Q.504"LL;*6V-ABP0T^)NS$I["QT]'MG P1V6;6M6:O_Q]2Z5
M!1&9;B@'$@S&;V*CP1J0(]* I[("EI!7,2RLBBWLRVL_5T:FP;SC^@QRSXZW
M:[HDG::8EIG)F6J$Y(P)$%E+I<#OU7YETRQ)V;<0EVW.@ >$JFSJN)8[C:*_
M@.,Q%[/"L^H%7\==B\CKS*&T/[6&^YD]KO&(=A99#\YXPE,P1^2CN>=;I1]'
MBZKA9O>+.A-BY60ZI4W>"*^BZ7-X=[>@_*]8V* ["\RLNSYNAJY^)._S(J-=
M]U;J ;3[U'&97M_)=V][^GC_^R?1IT?1K_GO9$-^O,9TMWL)/SN.WAY'W[]X
M^L/3&UCL81?KH&WIT@^T?_.IH1H_/,LS/V[[?C8CN5%_L3'=R'Y?]S(Y ?9C
MOXK]CPH4%3HH>)GEA8>X)XE5H0@@!-?<W<]:LR]5IEIO5"AHV>?J@!0; 9?U
M(94:XV2:?9D5B&@S;S/Q ?G2K]!@V+]V@P%5V^@72XI=C8:37ABU QJ_T%O$
MNPYX+)WA(.74&EZ9A8%CYIM!W/C"O=Q5AG P^2M<FR?7OC9'-.F LEH35^SM
MDQ#S&X7)GB[%\P%3/+OV0VMJ)N)(*:45P<FO[M<N2:2>^Q=J1L)/4S%*5K,K
M9-<A'2#5$%ITL<AJ,IA@^UMV+8$0NSJ@V!YT; C>-.%;!#+]@"?X@WB"_:=;
M PH.:MI$]4,9PA\KW/7/"?*KRS*QC9Z;JI"&*-:O!4R5?5WKX$YS@%8+3N<C
MMJ<_J=\;YLL'GV1/K(?JZ30A,XZYF'KP#/DU%?Y)S@X?1XOS@<\>Y,O?R!M[
MB5_;/5H4,E2Y:@*9%94,$C-OLI;U"GMFR-]SU:)A+70[,&) EORZ8PJ81 KG
M$]<46J0%@KH83/T9GBA]!H?8O3T>O6&W^)$&WZ-/>*9^HU.$9DB7%3\.M8GO
MIA3H+'*M2$#$V"FCZTVERWO1\Y>U%DO/%QGGI7Y;UGDSE;)-+?QN:?DJQJIP
M+D_S;QRR! O+HM;,5;T"WN6W99D:-D&_FI4W+]<SS)0II,EJY<F'5E\V$<T:
M0QIJQ;[4-;<NP(UG23W_VE3Z%\U.G3!79'>SJ:00"%_4T+H5;@>R7&"N'&\/
M)U-:2O2&KUVFXF!.GYS2A?YF/VB:*LT30W;C-C)P$J@^(;G@6M0%MWY<%EGC
M0(R_+:>G4C-B4@]2VULC;^4-PQNW6O<<AM:#Q !%;.>SA--F_D9FL0$S0LKP
MIUF:^Y4$WH/MS/5EB8Y-1;*6@9J*'J_A#@)7N%YY@PSKO[[3YEO[7\,GRH=;
M;CR<=_@T;)>)>?&0B;G=3,R+ATS,73DQMT^R^:Y2Q*IZ<22'M')+1&*U$""*
MJ&[6SX%EP:Y\TC29)N:19,YJ-B1W&EL-*4@A3Q6DVLU\.JA#.L6I0M]@L(CR
MWA*@M2[*1<L.N5-M4K@*Q+5F%-[.)U\PBO@*?@FF(_B0.RQUK[*'IC=G@_BK
MZVE3DV$1PYK]!0MQN,R\\*CW#PX"XGT. ZDIC5GZ9U5_CO&O\0C_["!=Z&;S
M:L6A&O^*[6+L,[%!=@Q2DGT<Q]$#(&TE%^Z**3'XM3#;EXQX,Y!E&VB\W"*B
M2<$XD\;C'M20)*-).N8#[CXCUX1M?:'0\_XB+A(?C8Q)UID_X[D4/$JM(W/D
M&OASK-Z#*8RN0TO-Z_[<P=!UAG2'X^&WW=XJ."36XN3<)[M"%2QTZ3/>KJ0W
M80KXDT'!TRT0=]B9QMSW:8',CD:W<GD)W"<LGGF N6J%0MT,87#C->9-L\P,
M%LWS4P%U @:RX41G4 7;&,K'TL',^>&.?Q$V@I".B:@/W0V'H5.(TH"/>R\V
MTS7O)MY&ZQV9.(#0#:3?6P-EGHE[HPVF/&J "F!%JS6+Y$)DHZ.O="X-K1ES
M)\6;_"?KW5D/ZN*LTAN8L(#5@ZKQD"W'>F]_O<15M#"W];ZB7\S&3A7[62$(
M93F9<U_?%C5K1KP%D1&ML>/]S@_PJ@UFP!MK#+P6_%Q6TB]36P!D/=ZA^/<&
M[_2^\,5?-W/P)3)U45V(97=:HWP(?Q,8$2^-%YP"42""E!:GZYI](L35"O1V
MT.O?%>/T@HN*+&R\TO5?+,$5<NX*3?.9$?+_&NHW>3_6][HH]WAYC6(S$B9A
M39;7C H#Z2,;3(RN8>HNCEUR!W1XX_E"@N(*\.&XV-(_R4:7AD5F?6442_V-
M*,&F;?JGU+H[+O>)RH)"J<:YZ7A/7]^+!;]FBD6IBV9LN5\.;9/S,%W8H.@6
M7^P_W4FTA&P+U\]%YJVAS+46I?1L%#&?@QHIL;4:; AG4\,!S;P?-@RY+EFM
M ;W:--F4ND,)M\(<@K1"P6:IB6U?,7A;%)(N;W0S=S&/H<<L0'!-8(CY)0U_
M2<3@F_"$\[PJ+()NPP0MDE6PZT7%>2D2K[QA6&QZ9$1)VP*^[E&8&$"GF7E^
MS4.2]H\F:;_?.DG[-F_2K"B2,JN6S4.:]JH0BS^#2;?DR-DOR<40OL*WP<D$
M)0W%>% F#$+3D#@ZY6=H3U@U%:<:#;-09;8+K+KYU"HWSYNL@-&1F1.'@CO3
MD8#UDM@5YH"G9U6>9GOTSSU8].S??^6ZY\;;UA_0*DX96Z( IW<DC\WO(,_G
MU13FH"=%;7%Z/93#'=@:Y_2)4U,]W/75Z.-=%LS803<.8_DR6: ?'K) MYL%
M^N$A"W173LSM9X%(VDE7P$D.=)_*NV-I(,F2KAZTJ9U$$R:(PE3$YJ5(-J8;
M4M7&%J""/ .O5P/8WO/]D+IJR_&(?.=%U7!I4,SQ>!.RO/SYEO9_X!79[[!>
MLZGA9@X_2WV^25(DI=+:<>YBHY;G*/ZL\\KH N6C-&[[PJ >QO^( 8 0MS.&
M;KG#DO_V,U&TCU_G2BLN_?4V6V9!C));W99*J-B&M#3NQS0G-PPS@""$^"YU
MI@%U=N::@,8F8.#!4U[;IZQV[?:BG0)JDDH?F#30_1M[25BB"NE#JT%)>8BC
MSA%8'A,A&"A@#(-BL:S3LP0T.?.L/@6>J\ZJ^C0I\W^ITY;:=MG2= O];AO+
M>TN;>I'!N\3! KM#3!X?76$N]ZEX=DW_)#Z$7E<*Z5E 3^.^&@T8;'EP#CN<
M,Q1MKB#@B?#5:DHB23G*YE=CQ"@+!%Q?<6ZHLY<<B.3XD,.6R%W496W+O48@
M2J; :U.Y7_O=-7PLI&7Z\4D!AM\#H6!H*G2U.(^7T#W)9T N%V3 9(^BCVS+
M%UIY8%93TGSN8>#XQ*<+!<96.]S?)1T^U>%$?*8( %UX. ^6!]\]JE?5=Q92
M8Z]GGKXGXBR[,;5L)8,$( ]$-!BF0\,@., ;J'&<[R%J#0R# SE*H.VM$1]8
MW>N>?.I2;DN6(@';@B_B>IM/&R.(%&.%ILD7+;0IITR\I/0E'H7&0/FHWX.M
M- %=EDA%GCE.C 0V 9=\SAB=RJ\6\,B"285)-I3I<CX1)AX+424I2/+OGFS"
MV8UL0K<7/VJB9#PZ7,Z9?N.<;'=R)WY-<FY;B#WYKI*$"A,T*YT."Y\ -F12
MOL&F@0553BVK"MM)#<*C&JNW5$#T= 8%C4>V:06LUY5AU^'7.QO2#C:TN'*'
M?S"A5O\-6HCL]B1GX"\BS<=)IC+[/6?*(SJ<+0M' ==*'Q^>C&E6)*N QYJ^
M/9@+7"^-90SG$7M6L1D'Y"=GLH*AF#='_HMI0J2#4-^ AI1(H@M>*9-8[2"K
MUKS6)%)EC!*1\)!88C8#H@()DHO&Y>A]-0/8WJ>(8>6 VGW:1A)#<9QLX5--
M'\T05, HB6G>I&1FWVTL[%7.[>G-*8_Z/#\GW7&6+VP,*ZP:2)2RLM^%H,M8
M&;,1YXH4-KJ#;"5)Y"JG14Z8P8PM*)A*JPH[Q(3+/(IQ_ JLX;I_&QZ_LOUY
ME]Z3=3^[J74_%/ BSDYCBS.#]7%G.C4IK/:BLJY^ZCV -*<V6_*A)8[W'I4$
M%8D. #\$#:%F/5\>"]<"F[>VX-"R6'E/0:1A6I&LYOS5)^:28L19OW#)BA/E
MAS#F!=?QU%69I]*AY&O;)M^\VG]V[;6@FYG?C'LLX0O'.^G!R;3N68MUI3=<
MT"VRLSH>(#?6/H6TS>8+:7X57T)%%S'-A\V!%*O8R*%Y\GL^7\Y[Y([K?1]/
M][%K[^(S P$6@?W*+#P:Z'&ROKW&#GWD!1?1 PFG%(>"X-S5P?3Z;3!&A9N"
MU\K*[;E($(W!%VE^H"L&.^/P6U'8<KN&2ZFDJ@N*&L57>9J93C[#E(;#1)D.
M 2&]E;5#IN6".87_C_DDS4 6UZDTP?L:L$O;I2SV'S_D+&XW9['_^"%I<5?.
MS.UGX:_>BK5;5Q*TFJ0_J7P.&K</];MJP^9LC"$R\E;[6<$WU>KGS;)6XHFP
M>3>1%-,4@D[]M=<#8ME8_#;S,MA,])QLK&I:%=4I*I^%*]D"9&U4KNNUL:[F
M^&29Q1KJF25HXA ^KW5=QC;P*9<&R60P"=W.%!:D-=5YP 4FX-[KK*23NP5;
MKYEL'\]W%77&6'A?;6FXJO6-F#5/%!>[.:/YV>,5E1$F11 /EZ]#/Z1DA> 8
MFHZ&M*K.W1U6WM8D4E.HPT;+$0<Q<M@6RYV1<\GF@EWN,PM['40".X:#=0*'
MLXVPW4$*FOLI)2I6V'8"D*$O\CKP^YK\]VCGN5["/<9M+SXZ+@UW6;7M4]>?
MS;5S)GWG_#&L?PA'.1]%[_FTCD="]8W:&3-6KH0[DU;HG8:"5QY:!-@^G3R=
MJOA2^8,"@ 36M>+SE$9'E_T2).LS2.,0IPI>.BRG;;C>65 N'BJ6\P59H',7
M,[*<W #I#KD'W7T]["_TAN''LH=X$DI K^V'\S0UD2=WM:O$7 L9[[#=>?LP
MIY-*2Q:THR0OJ^X"0^8OR,^ =?/R?D*^]&Z3WS6M+4T)_"V!!VA[ 'A?IFN!
M=8=B$]/U!N4E[UD2A8WIWF1I-I]DM:S5TWUS9LF^S<HIN68K8,A+^N+.P347
MC$=\1>[7O-@O%Q'KG12__09(__I:SUHD6E@K#K7,H#38[$VY>1VK2C(I/^?>
MN8JY9X/F?6R+ ]+OZ_1Q('AM75;GI?WWF#R.IF"XEM'+\DH06HC6%'4O?J#>
M'W>DK>LN82<SHXUOF5Z#\<1# XKMOK.-NC'!9GOQJCD]E2@/@[]Z5WRAKK9K
M-*!(;\LW)OH;+Q;(-7;N:5TUS=YRL<TID='F8*31QC]&#@:'Q-O=^)PU.WP\
M"K?X\.Z.^IM;NG!XF3;S"6%O&8AF#,WO(7-/A.O-H*K YL1@?]GY@SL@MYL,
M4]L)PZ+&@#:(\IMU$^EKC%#I3>_NE$U&#@#*#+*D-:D@M49L#Y*O;2F_>;7_
M_-JCI<>T1O/2^E(:/'\CPF93X^.A+C(PC[@_CF7',A11'#13\BSS.[+3!7V'
MQ5M*GEI=!=I&#M#F2X8A2%"NGQ!TY:/W,?.BWWFWGG-441@<&"0#%K_6\6?'
M45$U F9&:W..TVHMC"E%X9OAW2S;89O7)\BQC@&4A6T;>ZCUP;Q7N?7L#I<M
M.V^Y2:L%6\+,V^WF?)<W<FEFTK&0^=QC79B+LIXI[ BH(G)!&=+E4 &D.F@E
MV*X47JII9N!9FF9U6B!-%DF:!V4P4@V4HZ<- @_^%2IUW3(P&583A9@B5T0M
M/-)\)Y]KAF*8EC+K(N*=ND*RH,'CU68&O=/U'UG6S)+SJI9>XI<$W%V/[_&H
M.^!#X<5.U74Y+LW+<P78O5[M_9)<-,:WZJ_^T$'2-)46"A62PJY"@KJH<W2#
M.(\V4F(LV;1:>-TX7E?</\]WFIQBM*TP\"@6U/9P==GQDNDY[_&@CBDPFN6L
MLOG5K&T6L__<V02<($L@[$$256KJ%<8N[45R<\R"A;:"6 F5[LXF*W.VT_3/
M74RAAX@PR=:!M&S0W[V5;O+H:-1UX;U-Q]1NL@E<+=A=SLAMF0/8?\@!W'(.
M8/\A!W!7SLPZN^R:NS\S,['%4Q^DG\OJ@D%]CMK8LVO(R8;^<U=I"MLW?:!9
M$TD+LR3F'$*SKG+8ITP.GC0>V6Y0 A83O"RZ5*'P7["O?9M(2 B L6BR0ESQ
M\YPF?/!EEXT)/AJ*_TR-;:R@\H$O3K,<G)"H=UZLOF(HKA4?QZ_^6X*04XDP
MXTP:K"MLEAR-78L5BZYH4B3EY_\!B]3=_<XME="3!R5TRTKHR8,2NBMG9CBD
M<_PN^O7XY-W1IT_1KW\Y^GCT_N=XH(Q6<#CLW4X5=>,SM?E02!\MEU@S6HJ,
M(&+ANWP1W@+_Z'6/9KCGW'G;;@1K3_ WO"LN9RS@G=/;^M^_H+/YT^M7']\?
M_NU7&G#T]NC-\>'!+Z8/S[M#FK?7<G#6/B,\WAM?U3U25QK[X%LN_>75W].1
MFFME\'?-=]';@X]_H^L_OG]]=/BW&Q_9J]>K'^4!;Y/Z<_2IK:M)EGZ^^?>>
MH%%(K[O0T?N;?_,76G,<@J/_>W3X]Y/C?QSUM_Q7_&57V<U_)9E\%+T[^GB\
MQ;"V??"_-TM_1>\@DHMUOLU,0=)WWF3Y4NZ>>MS2I'SZ8%+>LDGY],&DO"MG
M9LVJ0GK_Y?CU\8EMD/3Z#ON2MP_0=/3-7E&I1^,\'G&91B35Q\R2MT0-25O3
M8+TV(F@AMHK*9)Z%R6<)G7!40VW[(122PNR\ZCE-!W#"W18?,*0JR&'Y4264
MG-@.YU$25,EZH_#1<YUA3%:&9DZHV#@9X? ,'7BFE^G@XBQ;C?5G>AX0A8<:
M/:)9^I2A' XCZ?(%A.-7J,89 UUMLW;O2[B(D1$5P(5:,FQ%T3:*31%,"[(*
M 95!Y_O"\7>;LT<E;>&)-X=F0$PKBZEY%!W/.O.,()8 $-$J-F@W[]4B&Q3K
MFF\T:8XFK%^VK(R*4 UWD,%Q#&7P&;K'-=07N8=C&\1S9LP,V./H=64AD\S+
M*]G;O.%_-3&ZVP"S.7ES"(^^+VE^=%"H_BS/ ;+)Z6A!'TK!VW##+)%*]O(%
M639I]^RYC"TC,;CFO&3*"\Y[)[85E;149IYLE$BR -$!\#DU)6Y!C@^]KY3K
M5)#8'L7BE$2!9.BB-*_3Y5Q>W]AN5_)TV>(>#H]N:@:'L9,C5>Y>@81V*775
M-+!=/U%/_T#M[L[3Q[N18YKW@$B83T/NK.,9C\*N7"\]V%A_D:1#\Y*;"A3%
M;%F0)#DMF.-D$,>[=.T&.R  <S\^?,D=QJJ@ET12&C81I,UQI5TR1AE@TORF
MXFM?OJ-H,>1E&7A#SP2L?G# >6G0 A86OCA;-3!@&164<6]J&GI) ]N-HS7;
M:19RK00HC+7;RLHEI3GFT+FI+0 644 !3(X2X,?,K$[0Y>M\.-^BRP16^=Q.
M#8UR)DVXNY-OYMS-=;!=D?TV^]6[C;=M9RJNLCTA['5[\C;,;;G%RIWW1#;;
M-&_.*EJ%=A4S2I/UFOQIGC?) A0Y=:YD%8#K_>M?A2J,69TL&4YGB@6U<018
MLZKBW"#VAA$K#IN"(9Y[ $MZRKGI>T47FR*+(DMP;UD5%1\?H4PW?T;IP#F@
M@6UH6DE;]:RH9 "*=:EA&+A1SM%G,VJ7]2)OEU,ZNN >.E]W>,>CK#Q-3BVU
M#^UB383)U]/-##S$_)G?R2;+G70NC&TTY^).ED=H/D<KN6PZ=@;S+R3R9#WF
M#!O!KX*/#2I&<^G&I<I$Q80I*S%,C0S<FRH[6J6X&"V_P&^#Q].W3I(IAM *
M687'V6GE]D1;Y.'HT"=<0%2D/G?UA/::%+%F'O^T^=0'QMQAQEPQ.#:SYNZD
MNUNQYGKVA9C2#,(LV[HJ/%LC4J?&[""]ENNE^%IS70)!/..62[K$'XJDO)<T
MO#?#]M9=#Q9[.LF11.EZJX*&I^S"6?PA_ZC=AFV?BR3J+;&4:Y/4=7#PL^H"
MO#.:J8<?,!ZMNT]JT(=TOH>NZADJN2LV% 0VS)+SH, "(N+/%>FQCRQ,HIV$
M"X1D8Y%4J2YVS1""RJS>0&,S1)%NGL%GI6W7W9(/[]>EUR3KSWD'6(.;!5JK
M]7:,:A0= Z4\5=(7- :!L2!L$4V;+9K0[BQ2%.J)J,T<OG_@4S $9TBZXKN$
M-$PVQ*!NNF(ZCBDK8GLK"G]1\-A<@;66W"P6FZG_ (:Y*D@X2[QRKWP.BB7Z
M5[$*5\L4@PW,M6R(>^(9W@R1FB<IF/2B%X+"%!]#MX*$_R,F=*E\%#3G^S^\
M>!ZS[3YG?BH#L0DK1^\KZ\'W#YF!6\X,?/^0&;@K9^;.T/%YW=235BR?$Z<5
M^H:/U2&V4%;*>M_95NC>[0$</L"G/X\,<]P0LG$\X@8M8F!Q:48BSONZ8@S3
M$64#X%RC(%KQ_(9<:ZV2L5ZI6 BQZ>T(R#QJ(_#T.RQ];Y\@SMM"=E:'LC,F
MZH12&!.+LMT-Q *4/FR-[U+[3+\:UH*;"Y2F!*-,/%!C05P295MN^A42XY'?
M"E;L]N2S>,:HL4V9K<P'R4IUI^LZDZ()3F6YC.%WR88S'=)A=.&SIA67#^VP
ME:4_*#_ILET*:;%W+YV@4UC>XMF'C1IV(ZE#!_&PHU4K&YN1 76 A,!@1])K
M>(YGS(.@?_2*7/>?#-S]$JT<C3/""Z%W2!Y*PEO]<AI@E?WBL)8T'<[MT\<(
MB]F"M# NJSY.:V,D<MHX521ODLK[J3NA6BN]+$$2<$^.XLUP]KFC: &%X]$'
MGM5A4:YK.\GH*TJO2_T:5T,:S'!MVOX+L[LZ+K"*9HYIT]ZV3T*1%S_JGJS@
MS;1W[2TD7/+Q2'SRWAK&?K6U<%KP&>,&G,NPUT) N1,JXYW);JQ%#!R6#$+N
MW-*;>Z5-_<XRK2!?!0VK#'3:3$VCS%(JIS'Q'T/V $>L'&:D]&Z5Y2Y8*YP.
M)#":UL8W!HI$*Z667Y-@#0HK;2 ^M8$U+C9#)U,@"&/71C=&A!75&-R;S"4=
MT& -@V(YQ63^KO130P(<!9),32.6DGWO-"?I+TT$Z0_]KS&OQX.1Q9$W=-\I
MX]#!^4DO)(@0^U[[_->H ?V4%$J:&Z0*9J)H.-GT[-M8-X;2^GC/;80Y TD*
MC* J)>0P$!>9U%7"C-SR0OL,>,,5ED3(/H>J5S.7KC'%SD%:1<5-Y3HH#6P-
MTF<(R!2@6/P<^1>[+R7%-<\+9$2@O/VD2+]"]8^F>8TV=/S[?CM''[?Q-9 C
M;.G[/WOP_6_9]W_VX/O?E3.S'2KP]=>$"O0_XNV'7][_\XA.X?MW/Q^_.7IW
M<GSPR_')/^/HX-.GXS^_>TN_B=[_'!V_^P?^]O[=)U)N[]Z_VZ/?G!Q]_/GH
MX]&[PZ/HX-V;"+\]?/_VP]'),2Z,#O[\\>@(]W^AJ1FT!:^UNNC$-Y&@31-?
M,>PX*]!J%<\$W.7&Z:Q_I9#H/?F9ELYG_WD</7G\Y&EL]8M#I[-Z^5BEGR\R
MTKIOQ6DU931E^HA,']<8TF=>V(&.\H/@K*W\,6E_X[!##)+TFG 6.Q,TD6XX
M)@[>);3Q;"4XPY: 2QU'9<"#4[P:++?RFL_H2'_\6@[41M=C_WK+HM?52O^U
MFHQ'7$PC^\4W/*6U6W3LE3V+8T]+\5LU$0NZGX8TT,9/__@0D[0N 21Z%+V5
M>[P 3M?(Q4K*G602-UGHRZQ9_=[;[[ 9=87%?_)E%O_0/V2FCU]OM?O'D;RY
MN="BL4JPT;7^Z=YVV40Z')O>6_1:K; ,7TR_F"T9UC-%O_26H[W-DHOHO]8"
M]8T;X>F7V0@?&'_&N'#: 27#_^R>P+(X@H2HU],,K<48JZ59 H5= F)%+N-I
MG<PAU-'T+JG1XV&:G9,?M[ M$^DB=1/Y506Z-;KW81]T7HC&CM K[!8S6X'P
MY& O,+P=W'_Y.:.GT5=(8(F 0KHO,V].Y4%>WSWW2VD$8&]!-)='+H%@.@$:
M0*5-[N4@0B][UV!$:N[?NQ36!<ZK ![(X9B<['3M:3?$N",/D.)C$"#5N'4\
MPM,R P;J.JX3$#XCRN.9%]XB1\$:.\7^*%ISD895L*/1M$/)'IFLAXNAJ[@W
MN8(M;I3@LH-3[ V4&W()4; =NRQF@T>?"T$#_[LE>R9+$6&WK05I1E=-F\T1
M0V&(M491P ?+_X" H'_0R:3;Z!^F>8A&^>?5-.-?)VTB@\<_)@ESBNK^E'_)
MUHA-HSN$S_7-_'!T&N1-07.2I6>\M!+/X<VO$^/VO[LHW)!\2O(4_Q!&;:'T
M0V^J)F88JT;!S$\DM&6 "!0VP2'C22DXD.@.X8SU,D>HZ%-CQ(@;!'/,S[G!
M-]C5\-:7IIOQ/:=Y*IQ0+8"F.#M%4IHO07 LE0VC2XQ$6_TYDP ;$!"5D&XP
MNC4I0!4KP[0W*\,O9(CL$*80]OZNDZ87,(\6?263L<F?:"M@C=IZF4J'&.XW
M93_*3BXF<8D0MWF:?%@U:V$?T]])2E=S9?B&QF&B:I$L$K/K[O\BY\&L%4#V
M7(Q'YN%-\/1&E"+$*7TN Z)H.IP@YKB]IFK,+1H4-H^3QHWT21 X$GM%HZY6
MAQ.\%W$_\Y1^;5#8]C83,*)M\;E6:@3;QC 4"E4XV'N;P.9?+"=T=$G,5J!I
MB2,/"]^>U=7R5$R&M;&X@&LT^KG2X+!"KL(5PC0R'BHY)RG%F;]3J992?#B(
M^SAG9<02:6::KE[AE(D 6JCU<*G.T LUG"^?;:GCY?)U&OD.FS5;A@F?/X0)
M;SE,^/PA3'A7SLP57('OOXPK\-["*@Q"VJJOX8B US)98P-^FRDF$99")L4^
MGN4+(8J7!VLB4\IX![(D$FJ:9Z9'"&LR"$F;:H2T7:. AAHYK%7(@'1#XV@)
MF"U9LFDA]C429Q'YG_0H.I!>=JTL-FW?LVW\ YD^FUSO0)OF*Y_"UK7J/J^*
M92E5O+64V,B/NR:^)T&8SUFVT#1=?ZZ%QI.+#COSI7=#&2U);R(O>IZAUAKN
M![DK*7M6 M]("X1J;%?0=89 5:^?=Z&^U_(8;LW'-=QQY-44N\(_K[@XB!]H
M5IL<2' ,3TW!VCSYG)EQ(E?.")ZT6M;:K6"^R#C9C**@9IJK&SK0^)). T^]
M8^CO-\$,DH%)4/1[+"-)PFGP!L;X=K,IQ.@0_X?G9SPZK4B_2#*=)%J9TB=[
MO^*4:2ZF-,++)#OK,ELIK"@S-I XXII'UKV3D<PY3;30O%GR^:*Y.\^KPN[#
M(KF(M3&\G3Z8.^@5+BV8,Q=;=KMG@EJ)8LILU<6:CA[KYLRRX#,_LC1]X"%P
M670X0Z JEBI&KL9PL_HH>DNJIN*R"S0<&.Y=.CP$M>,6M910(.!%QB]\F,\R
M5YM6TCYNW8' H@XM8"S'P:T@ET.:MK<H2*LF3!,NY7#)5)O"1)M6)FPIE#2N
M"1 =!YJ\1]%K.K^D@L1+#P 59E%5Q-, N"TPA)K7'2+%EWB\#)"-J%"#"\T]
MLBQ/>,.1CEJ!)KIB7)<) G06%-QF>VWIS'BT?B4Y(-%TQY8IZ3-2'5+NZHN?
M8_,BTX.C>])R4Z3*Y)D*V/B7B!=SZYS$EY''NH_P,HY)V3X2;GH:KE[A_B4T
M$!X6ZYR>LU1DB3R$<T8X]BB,I(N4!%L0*'?8*;B"@7/-[4S7&C@7Y.9!99-B
M>^-.+13?@0,L;7!J647:B)1:1*X]N#TQAER6#T[2: ZPN1_IJ1MB@?'71RP_
MMR8RTP?KK;THUY")\< %M\9]P(5<W?2(-W'#H7"K,/VGAL-?^Y-C$(VKY=E\
M@R+?O-9#:\91X5M986RR86UL.D;DJO5#KQ&#\SQ=V(F6+I)6^H'P-0B_<4AJ
ML9*0N?;G BI+T/$22!] =G6MNS H$61NZ <.5I>5][PU'X<[S3GA.?,7T/RF
M2PC3FW--1^ND6ZN:'F$^L[493I.C9HMLI;UU >5CC;AQJ&C:8^>.+1J&F9&%
ML$AJUF>D',^PRJ*/.;8EF0(-TT,_BQ46^@3=D)$&[1-Y 6?_H;;.:(2NN)R-
M([]S@XX,&KV)7<?"*^U5!*D\E)Y;P,3_^/NA<&Z(689DV,>L7=;B0+]5=(-,
M]@<5/$Z6F4R$GZ^@546W':!48:@MQ")&8%Y3$C9/$?ANQCMLR'04\\J48 A-
M$L==^YW/G1!P?W$!\3#C(M?:R@XK1[TTT[H/#N C9J@T(D@S7**Q?3KL:P7A
MC"8U;\[4L\MZ@-9:<S4V06>LL4&1YO7C,2WF)YDB$Q" OJ+R@"B3I]2\^CVQ
M!13.X-Q(^1,2?5D)9YL+GEW7$1>%!VM\'FJL:95IX[7*-H Q!D@PF@VO7RZT
M88B+/ 1A!SN7W;:PZCC9FJHP=H#";)GIN40(AE\?1_8Q+A,LR/-J1BO#H^M6
M,M\3 70SK<1( *%2;[@OE8DR]960X0)")&9G7R-FW ".%X.#5*&/CQS>HD7-
MOPD$A7O>+JUD%WTJ.2:Q0]\_[E\SAQ^5J1C<(ML+M<A9*O'&V)KW\J/DD25A
MNM9/QF*P</$4<N\G2G6 ?OHU+\OJ/-'A((FS1]ZHS1%KB@Y13H@&&9?E.W(J
MF:[ZCB,:=7:*\H::6Q+C7:IB%?S$+::8NB4Z3X2FAFO\HQTD)"2'5] $.''K
M>R*>B(TZ$I8/D+N6\0AB' HB009\S.&-3,-U[#C'TA0[GRP9;1,+J%_(IC0-
MR\M,GFH-\J)<O-]"XWF_5;2$AG))9'%LXJ)KM^(=/MU;)KG^])#DNN4DUY\>
MDEQWY<S</OF/%U/@1G-&##K'E4W@+LH-NLF3F2HC.9(?>P)254@L55I=Z0AL
M6=1U"TGQ;"$I=R.?8W6+;)+)=QD:'1[P!1C<4NWFN6R,Y'6>A45^ &24I%[-
M61!E[^3*O-=J*=7 :QUBSI/Y9_""V=0P,PJ^'\[%E(TU#@:>'[Y BD]C0Q3$
M<R2)130\9H=!%#/^Y8.NS#*90+S38VJ^F R?Y?OU/ ST]6N9;FTI@?6 7<Y2
M F73M:"O3N&97SUH^FNN-+(@Q>\Z(0JY#9;[L@#3U0)=-A:PHS2C7-VY),.#
M3!+I[#@>!9TCD7GI!B_$" J"%KO7'3FCE?%#9\=#(2\7YMHFRL4V+LY>+R35
MCS_9^!)Y:_*LM<&DCMW5B939O*F]PJ5FE"!0+6O#)XS P&F=+,[((L2L3LB2
MC:4&@M[6-]TWI)8' U @,5TJ:HD_APF4C:QC5C%>V2%AU"_%4 )#]:QY-K-I
M=SXU<RM86#2,E(R,KG@# Y6<?G,76Z/WA]SXABBLK".(\+F0^DI \+!2Y*H!
M=__:@55X^HX<E)0,?PTEN8TWM1LO\ 83?E4(#6<"NGJE<HCD_&H\VD$,>TT/
M6^U_NLM-23G1*9)#<(>0\-@&^*]FP8;/NZ-[T9_Y?#>9]W62R_9"Q4P,4IOB
M%/XBVTK6C]/Y)',N,UMQ+%9I7(V@=N!#]',%\-&":\(^J@HUW'!".<74&B+Z
M01#^4@A,PJ@,J=BD;:I,NN!"E2/9-9=T;](*RZF4X^L'>D2CEWQ@0 % CFW%
MV%Q#<.=!ZNNLS"X8=\U*I#&X9:X3,+XU<J/:MK ._\9+!:MIMYM;R^LZ.Z]2
MY1VTC/M8T<4"]E3?.(+.F2ZAJETBUQ2<*Y9)ME/">63Y2?Z@*?F&#O$>2(7E
MP. _,AM3+52:9+2V,_T%.?O)E)<S$^P\J+V'<!E: *]\^)K#MPK"K(X8$SS3
M5J&!2>E"ZF*<<F;(L#+>T"YB"3J\4%9H-^1#*:Z SY8(8&%.I-G(9ZZI&9LC
M]T0$WRCUEK0CG2]:),PZ.>.!2JL S6!CNVH3^(0:##+QS 9G39>5GS08LNP9
MT=60$9XJF\669CZ;Z>A^%WMU*1?,D&2L?(RF!CF$QHSY/""G!)EM05IXIHWR
M83 %@P2MWR)$WL6J:X\/0*\];%\UJ%&N8*@S-;=GJ#^*_J+ DT#/K0EV\EGU
MM.>QX%TXTI;Q%HB[T)O F%,PHQIT,.;JJ0AM.=3!NYCD3*FE%,77-%Q%TK E
MFM0YE,XG%AT.Y&#-/-O?-40'=C(.]^)\/_]2)70YT&G=0WZ@%<ZM."N2XG.@
MJK9%*8/VETQ RG.63_+6_MVT2<FXG,2X.RY"SB$%+WK.ARD[5S8^%NK*'>3&
ML!&.ZA6;L>4_U^J'P .8Y22U--0Q#6(=?.R1>]X8_[5DM>%0^D6A"B> :J^U
M@\\<GH$M0['&[""?KB2D$.PO$V,T\6'AR<P;.[O<0*:LPC_*XAA_91 4AY15
MUEB#S $?I%F%MTYL#'@+U8U:S-<!\.[P(=PR%O[B(19^R['P%P^Q\+MR9JZ@
MN/[TA?"0XD*\-C;6 9*,;">*!OM4];U-(4R-A#M$C3*)#X;H9VFKT@C"8*YQ
M;/6E1#(.FU;<8,=_H9)L.DM&HF.,+M]DPNSR#^KH,K(L)941#M):EXE\^<HF
M<,&&D,Q=N:*M<[\T@1E=EFWO@^7EV09JU1L4&Z>^LC3-3OCS4<:06VB+-#9K
M+#VC8?!;6R6.RZ\6U!;EZAG+XDA@HT@P2-Q&_1IM! 1_VM%]:G3;,#H(Z&R^
MVD01T@V /W0R^3<ZF;QXM%4C$T:3E'M,>#_+:EM%A%]^XEK[UEI@1TK=3)]X
M&-0TLY 1@7(?6Y;<#!CZC3();+:2+6ZGO<B*<\3_G^SV65LW1O]M75GWRKRQ
MX"_M3N$L<Y\CZF-&LB+GNJ$>$>UN3]3%+L(*P0==0-XQ^[3&\9=Z:_/35"*4
MXE+0?%1.ZPQQCZ)2&Y%AVJK5LH9016V0;%4I,--MRC%(Y-T2E5]8UT7&BZN)
M!F9U[H0=:*!%EIBH[3HTG,8Z@@9I#ML'_0:DC13 6 )/0[PZG/_4[Y/A XG#
M 7+1#*(]_OVOD\+Y7IN2@$OV!6WXV&Z6QFP$\V)=>!J8^8L;B.UG5%J4\_"P
MS(42LE#ZD4B8H5 \TV3UN5=#I)WP3 ,__#K_/=IYKE,FYP$,V!FYK$8S^U3&
MFPZ(7XO$*LY4(,%QS\OA2C%9$JU3@N6R;"2\[1$_>/9 9-4[TV/8P._0:FY8
MS%R[OO@OM%$?-I?"MH)2UN>V39@-9 BXNU1_A$J62DHS2,'W25&;*=3TD853
MUER-A#47Y+D9KB#A/G"H4^5@D&Z4A>;NS2\;7]MHTS<)I&5>MTM.N<_R&H0@
M_AA,*9?-#9G'^A].FXIA?UQDIN*(7A$<8C]O>[75N<.^_.W#YHVVPR;KZ9/M
M=4B\1HG$9OMPIHFV(P-!Z^6B5;(;V#:VNQ-D,QV+BT0VN9'QAC#%QM7I7YPA
MBB,Z^M.JYH<*6A(_V/A08OL-:W-$W1.<B)%V5EVU+LW]DJGR,7<JZ'N7#Z*#
M^@^M_ )VP\<BA<?P("Y1!PJ("1FWK8\3<D;*XWPV\U"42T&)#>0'[;L]/C%U
M,;1>V1%@Y?_BW>+L@N@RLV!:+T\],B?^$2]-%L;=X"!GR=1&S7=3>LFJX<2$
M^+^H2H6;-MUK6NA:,H6E\#?C)B+\@#.IJ_B<3U&[JW^S7DL+.)))W^1T*=/H
MD%3B<NXF@TSCYM4K$JA< G*VJJN<'C/G\9V15R;#$A*=G:#IJ'X:FP,*??8R
M,_)];O:@RVR-M8^.&D*K=:/$0YOMG@BWFX'DW[!PB\3DC;:34>/1M0NIZ _+
MJ#YH*)9 /W\0=U1/4).4G/8: DD.P;8\%-R<6A_X""CWQ*_R=_E6MK'\NG^/
M$VSC-]SA7;YE./Z'AW#\+8?C?W@(Q]^5,W,%S?##EPG'(ZQVZ.*YMFZ+:^$Y
MG.,(=25 [X6:+U<M:ZUCCVQ'\[,=QITN&!J$EV0X)^S']65F8%-Z35F8_MRY
M3?JO.@Q6J+XJN%-8K"PUT%6VPP<X+4DEE:SGVBK]3";+5!XC3.:90749G8G;
ME2?%AOX]PA(&A?N*T(045L[[9W778Y+Q6H[92$#%:7P;"IAD0AFS (+'K_O'
MBKC6)-( C&R_E*-R3[_=-2J/5L:2$0% (HAN1Y84"3,*J<NLT&[N0I@8=H%G
M0*:SK4V)F5%]?(%=J8Z?<%$MBVFG[WFPR+2T!3=Y:9 W,9EP:0#?87VV"8MS
M!^[93"NFH0?>W1S4,.0O#D.#7)3#*S)O@]?73<A:6M,%N,A.Z?6@GO<93K]X
MO_0O22C_^$8$6$ 9UW#B[F?4+!@Y9<+^40\M,;=QFT'XQJ7@$.:%6YDT4J)]
MJ6P"23PR;EK4<,J.@X.=O*(5BT)W)3:DWUFP\ABA&@5XQ(*"7^D/(NXD HSO
M-B)-[4M#'.;UKNYVJ?)?:/>] 1L#+L96<V;H096U3.U?)GD+N*C4&;0U]!WR
M->!20@(..:JML+FS:("KT2GGYC_:/ZT\R]H4NY:S(@?J5)>JR['EI @SHG6+
M6TAT)TMRE@7CK22O'2P,C6>VK 79O0YZ$Q#D2O&QR$V1BBB#0A$"$HJGEHM+
MT[W]'#>G?1-U?VB<YWG=+LU&(VE>D3?M* 4Z= !FK(8[*^C8+8L0.C0SV3 :
M4[UDV,T92V3NLBB3AB&9Q+J?HUY#.V+IU@?GTK6+[!Z:F::+\U)HA>EEVIOU
M.#(E'N'J"[X^8)*$&BWW="O+#T& U[)2F//CQKUG\MK>.<'%_C$R:RJ$@+)\
MX>\FX,R^)Z+]9IJ%2(<(3VX$C(XS6:$#MP8"/5@C_;L$.%YC5Y?S[] '](Q7
MN@JA*PG[=6B/-DB\'LUG[;'2KY'<#H!AB9UA,?FLB'Q6:>0K(Y@M,ABQAL8
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M4$L! A0#%     @ 5H>,66^5[E_^"@  @(8  !4              ( !6@,
M ')M=&DM,C R-#$R,3!?;&%B+GAM;%!+ 0(4 Q0    ( %:'C%F-7R((6P<
M -M7   5              "  8L.  !R;71I+3(P,C0Q,C$P7W!R92YX;6Q0
M2P$"% ,4    " !6AXQ9?I$)ZPP:  #S@0  $@              @ $9%@
M=&TR-#,P.#,X9#%?.&LN:'1M4$L! A0#%     @ 5H>,66MS'"O4;@  5&$"
M !8              ( !53   '1M,C0S,#@S.&0Q7V5X,3 M,2YH=&U02P4&
2      4 !0!) 0  79\

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>tm2430838d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rmti-20241210.xsd" xlink:type="simple"/>
    <context id="AsOf2024-12-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001041024</identifier>
        </entity>
        <period>
            <startDate>2024-12-10</startDate>
            <endDate>2024-12-10</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2024-12-10" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2024-12-10" id="Fact000004">0001041024</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2024-12-10" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2024-12-10" id="Fact000010">2024-12-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2024-12-10" id="Fact000011">Rockwell Medical, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2024-12-10" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2024-12-10" id="Fact000013">000-23661</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2024-12-10" id="Fact000014">38-3317208</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2024-12-10" id="Fact000015">30142 S. Wixom Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2024-12-10" id="Fact000016">Wixom</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2024-12-10" id="Fact000017">MI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2024-12-10" id="Fact000018">48393</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2024-12-10" id="Fact000019">248</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2024-12-10" id="Fact000020">960-9009</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2024-12-10" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2024-12-10" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2024-12-10" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2024-12-10" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2024-12-10" id="Fact000025">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2024-12-10" id="Fact000026">RMTI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2024-12-10" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2024-12-10" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
